Human TRPM3 inhibitors for use in the treatment of epilepsy
Patent Information
- Application Number
- PCT/EP2024/061922
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-02
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-07
Smart Images

Figure IMGF000009_0001 
Figure IMGF000020_0001 
Figure IMGF000021_0001
Abstract
Description
[0001] HUMAN TRPM3 INHIBITORS FOR USE IN THE TREATMENT OF EPILEPSY
[0002] FIELD OF THE INVENTION
[0003] The present disclosure relates to an inhibitor of human TRPM3 for use in the treatment of epilepsy wherein the inhibitor of human TRPM3 is selective for human TRPM3 over human GABAA receptors.
[0004] BACKGROUND TO THE INVENTION
[0005] Epilepsy is a group of non-communicable neurological disorders characterized by recurrent epileptic seizures. The most common type (60%) of seizures are convulsive which involve involuntary muscle contractions. Of these, one-third begin as generalized seizures from the start, affecting both hemispheres of the brain and impairing consciousness. Two-thirds begin as focal seizures or partial seizures (which affect one hemisphere of the brain) which may progress to generalized seizures. The remaining 40% of seizures are non-convulsive.
[0006] The discovery and development of a new anti-epileptic medications relies heavily on the preclinical use of animal models to establish efficacy and safety prior to first trials in humans. Because anti-epileptic drug discovery requires the screening of large numbers of compounds, animal models used for this purpose must be easy-to-perform, time- and cost-efficient, and predictive of clinical activity. This explains why two simple seizure models in mice and rats, the MES and s.c. pentylenetetrazole (PTZ) tests, which were developed >60 years ago, are still the most widely used seizure models employed in the search for new anti-epileptic drugs and are utilised as part of the Epilepsy Therapy Screening Program (ETSP) at the National Institute of Neurological Disorders and Stroke (NINDS). In the MES test, tonic-clonic seizures are induced by transcorneal or, less often, transauricular application of a short (0.2 s) suprathreshold electrical stimulus in normal mice (~50 mA) or rats (~150 mA). The endpoint in this test is tonic hindlimb extension
[0007] Despite the development of various new anti-epileptic drugs over the past 20 years, the available evidence indicates that the efficacy of drug treatment of epilepsy has not substantially improved and that about 30-40% of patients suffer from anti-epileptic drug -resista nt seizures. The development of new treatment options is therefore required.
[0008] The human TRPM3 ene is comprised of 30 exons and maps to human chromosome 9q- 21.12. TRPM3 functional channel isoforms vary from 1184 to 1744 amino acids in length and possess the characteristic six transmembrane domain of the TRP family. However, unlike some other TRPM family members, TRPM3 does not contain an enzyme domain in the C-terminal cytoplasmic region. Several alternative spliced transcript variants encoding different isoforms have been identified in mice and humans. The isoforms appear to have very different physiological roles given that one mouse isoform, Trpm3al preferentially conducts monovalent cation influx, while another, Trpm3a2 strongly favours divalent ion entry. The mouse Trpm3a2 form is the best studied. It has been reported to be a calcium-permeable nonselective cation channel that can be activated by several stimuli, including ligands, such as pregnenolone sulfate, nifedipine and CIM0216, and heat.
[0009] TRPM3 is robustly expressed in the adult cortex and distinct cellular clusters of the adult cerebellum including neuronal (e.g. distinct cerebellar granule cells and Purkinje neurons) and nonneuronal (e.g. cerebellar-specific astrocytes) cell types. Prominent TRPM3 expression has also been observed in early stages of the developing cerebellum.
[0010] A number of gain of function TRPM3 mutations have been identified. These are consistently associated with a broad spectrum of neurodevelopmental symptoms, with more than half of patients exhibiting a cerebellar phenotype with ataxia or severe hypotonia, nystagmus, and cerebellar atrophy. One particular gain of function mutation (V990M numbering based on SEQ ID NO:2) was associated with epilepsy in seven out of eight patients in one study cohort, although the nature and severity of their epilepsy was variable. In ten patients having one of seven additional gain of function mutations, there was a diagnosis of epilepsy in two patients: one patient had nocturnal generalized tonic-clonic seizures since 7 years of age, and a further patient had electrical status epilepticus during slow-wave sleep (ESES).
[0011] Primidone and phenobarbital are first generation anti-seizure drugs that have been used in the treatment of epilepsy for many years. At the time of their introduction, their mechanism of action was unknown. Subsequent research revealed phenobarbital was an agonist and positive allosteric modulator of GABAA receptors and that primidone underwent metabolism and its metabolites had GABAA receptor agonist activity. Very recently, it has been appreciated that these drugs may have an additional activity as TRPM3 inhibitors. The contribution of any TRPM3 inhibitory effect upon the antiepileptic effect of primidone and phenobarbital is unknown.
[0012] SUMMARY OF THE INVENTION
[0013] In a first aspect, the invention provides an inhibitor of human TRPM3 for use in the treatment of epilepsy.
[0014] In the context of the invention, an inhibitor of human TRPM3 is selective for human TRPM3 over other epilepsy targets (for example, GABAA receptors). In one embodiment, the inhibitor of human TRPM3 has a >100 fold, > 1000 or >10,000 fold higher binding affinity for human TRPM3 over other epilepsy targets (for example, human GABAA receptors). In one particular embodiment, the inhibitor of human TRPM3 exhibits >100 fold, 1000 fold or more than 10,000 fold binding affinity for human TRPM3 over human GABAA receptors. Binding affinity may be measured by methods known in the art, for example SpA.
[0015] In a particular embodiment, the inhibitor of human TRPM3 has a binding affinity at human GABAA receptors of > 1 pM. In a more particular embodiment, the inhibitor of human TRPM3 has a binding affinity at GABAA receptors of > 10 pM. In a more particular embodiment, the inhibitor of human TRPM3 has a binding affinity at GABAA receptors of > 100 pM.
[0016] In one embodiment, the inhibitor of human TRPM3 is not primidone or phenobarbital.
[0017] DESCRIPTION OF DRAWINGS / FIGURES
[0018] FIG. 1 is a bar chart showing CC50 in wild type (WT) and TRPM3 knock-out (KO) mice in both males and females. The error bars indicate the 90% confidence interval around the CC50 estimates.
[0019] DETAILED DESCRIPTION OF THE INVENTION
[0020] STATEMENT OF THE INVENTION
[0021] As discussed in the section entitled Background to the invention, the maximal electroshock seizure threshold (MEST) test is the most commonly used first screen in the search for new anti-seizure drugs (being one of two initial screens in the Epilepsy Therapy Screening Program or ETSP at the National Institute of Neurological Disorders). The majority of approved anti-seizure drugs have activity in this animal model.
[0022] Example 1 shows that TRPM3 knockout mice have a statistically significant higher seizure threshold in the MEST model compared to their wild type littermates, with a 66% increase in the CC50 estimate for males and 50% increase for females, respectively, based on the centred isotonic regression (CIR) CC50 estimates. The relative resistance to seizures in knockout mice is evidence that trpm3 is involved in seizures and that trpm3 blockade is effective in preventing seizures. The data provided herein also demonstrates that targeting TRPM3 function in a non-gain of function context provides a method to protect against seizures and demonstrates the efficacy of this approach.
[0023] Accordingly, in a first aspect, the invention provides an inhibitor of human TRPM3 for use in the treatment of epilepsy, wherein the inhibitor of human TRPM3 is not primidone or a pharmaceutically acceptable salt thereof. In the context of this invention, the term epilepsy refers to a condition that satisfies the diagnostic criteria for epilepsy set out in the ILAE official report: a practical clinical definition of epilepsy Epilepsia, 2014, 55 (4): 475-82).
[0024] HUMAN TRPM3
[0025] Human TRPM3 refers to a protein product of the TRPM3 gene present on chromosome 9q-21.12. Allelic variants including those encoded by SNPs associated with DEE are included within this definition. In addition, the definition covers all isoforms of human TRPM3 that may be generated from any allelic variant.
[0026] In one embodiment, human TRPM3 refers to the hTRPM3 variant having the amino acid sequence set out in any one of sequences set out as: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO.5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO: 25, SEQ ID NO:26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36 and SEQ ID NO: 37 or a processed version of any one of SEQ ID Nos. 1-37 lacking the initial methionine residue.
[0027] In one embodiment, human TRPM3 refers to the TRPM3 variant having the amino acid sequence set out in SEQ ID NO: 2, or a processed version of this variant lacking the initial methionine residue.
[0028] In one embodiment, human TRPM3 is a human TRPM3 having one or more mutations compared with the sequences set out in SEQ ID NO: 1 to SEQ ID NO: 37. In one embodiment, human TRPM3 has an amino acid substitution at one or more of the following positions R1670, A1645, R1457, D602, K774, L757, S1678, Y378, V990, G995, P1090, N1114 and S1121(numbering based on SEQ ID NO:2). In one embodiment, human TRPM3 has one or more of the following substitutions R1670Q, A1645V, R1457Q, D602V, K774R, L757V, S1678F, Y378C, V990M / G / L, G995S, P1090Q, N1114D and SI 12 IP (numbering based on SEQ ID NO: 2). The skilled person will appreciate that, although the substitutions are described in relation to SEQ ID NO: 2, the substitution could occur in any isoform, and the invention is intended to encompass the corresponding variants with amino acid substitutions in each of SEQ ID NO: 1 or SEQ ID NOS: 3-37 (or processed forms of these sequences lacking the initial methionine). In one embodiment, human TRPM3 is a human TRPM3 having a gain of function mutation. A gain of function is one that results in constitutive activity (i.e., calcium influx in the absence of a stimulus), or increased sensitivity to stimuli (calcium influx at a lower concentration of agonist, or a larger calcium mobilisation at the same agonist concentration) as determined in a calcium mobilisation assay. In one embodiment, the human TRPM3 has one or more of the following amino acid substitutions D602V, L757V, R1670Q, A1645V, V990M / G / L, G995S, P1090Q, N1114D and S1121P (numbering based on SEQ ID NO: 2). In one embodiment, the human TRPM3 has the amino acid substitution R1670Q (numbering based on SEQ ID NO: 2).
[0029] Conventional sequencing techniques can be used to identify changes in the nucleotide sequence of human TRPM3. Changes in nucleotide sequences that give rise to changes in the amino sequence can be readily identified. The nucleotide sequences of the exons of the human TRPM3 are set out as SEQ ID NO: 38 to 69.
[0030] The term human TRPM3 channel encompasses a channel composed of at least one monomer of human TRPM3 as outlined above. The term therefore encompasses heterotetra meric channels formed from mixtures of human TRPM3 variants and homotetra meric channels formed from a single human TRPM3 variant. In one embodiment, the term human TRPM3 channel refers to a homotetra meric channel.
[0031] INHIBITOR OF HUMAN TRPM3
[0032] An inhibitor of human TRPM3 has one or more of the following properties:
[0033] 1) inhibiting Ca2+influx in a cell line expressing human TRPM3 channels following challenge with an agonist of a human TRPM3 channel;
[0034] 2) reducing current increases in a cell line expressing human TRPM3 channels following challenge with an agonist of a human TRPM3 channel;
[0035] 3) increases the CC50 value (current required for 50% of the animals to show seizure behaviour) in the MEST model compared to untreated animals.
[0036] Property 1 may be measured in a calcium mobilisation assay. An inhibitor of human TRPM3 reduces fluorescence emissions in a calcium mobilisation assay compared to the negative control (agonist challenge / no inhibitor). In various embodiments, the fluorescence is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%. In one embodiment, an inhibitor of human TRPM3 reduces fluorescence by at least as much as a blocking concentration of isosakuranetin ((2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3- dihydrochromen-4-one).
[0037] Property 2 may be measured in an electrophysiological assay. An inhibitor of human TRPM3 reduces current increases compared to the negative control (agonist / no inhibitor).
[0038] An inhibitor of human TRPM3 reduces current increases by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% compared to the negative control. In one embodiment, an inhibitor of human TRPM3 reduces current increases by at least as much as a blocking concentration of isosakuranetin ((2S)-5,7-dihydroxy-2-(4- methoxyphenyl)-2,3-dihydrochromen-4-one).
[0039] In the assays used to assess properties 1 and 2, any compound capable of promoting calcium ion influx in a cell line expressing human TRPM3 may be used as the agonist. In one embodiment, the calcium ion influx is mediated by human TRPM3. Typically, the agonist is used at a concentration causing a response between 50% and 80% of the maximal response (i.e. between EC50 - EC80) for the assays used to assess properties 1 to 4. In one embodiment, the agonist is pregnenolone sulfate or CIM0216 (racemate of 2-(3,4-dihydroquinolin-l(2H)-yl)-AA(5-methylisoxazol-3-yl)-2- phenylacetamide). In one embodiment, the agonist is (R)-2-(3,4-dihydroquinolin-l(2H)-yl)-N-(5- methylisoxazol-3-yl)propenamide. Further details of the conduct of these assays are set out in the section entitled "IDENTIFICATION OF INHIBITORS OF HUMAN TRPM3".
[0040] Property 3 may be measured in the MEST model which is described in detail in Example 1.
[0041] An inhibitor of human TRPM3 increases CC50 in treated animals by at least 10%, at least 20%, at least 30% or at least 40% compared to untreated animals.
[0042] The nature of an inhibitor of human TRPM3 is not limited, and could be a chemical compound (i.e. a compound), an oligonucleotide, a peptide, a polypeptide, a protein, an antibody or an alternative antibody format. In one embodiment, the inhibitor of human TRPM3 is a compound.
[0043] The term "antibody" is used herein in the broadest sense to refer to molecules with an immunoglobulin-like domain (for example IgG, IgM, IgA, IgD or IgE) and includes monoclonal, recombinant, synthetic, polyclonal, chimeric, human, humanised, multispecific antibodies, including bispecific antibodies, and heteroconjugate antibodies; a single variable domain, antigen binding antibody fragments (e.g. Fab, F(ab')2, Fv, disulphide linked Fv, single chain Fv, disulphide-linked scFv, diabodies, TANDAB™, etc.) and modified versions of any of the foregoing.
[0044] The term "domain" refers to a folded protein structure which retains its tertiary structure independent of the rest of the protein. Generally, domains are responsible for discrete functional properties of proteins and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and / or of the domain. The term "single variable domain" refers to a folded polypeptide domain comprising sequences characteristic of antibody variable domains. It therefore includes complete antibody variable domains such as VH, VHH and VL and modified antibody variable domains, for example, in which one or more loops have been replaced by sequences which are not characteristic of antibody variable domains, or antibody variable domains which have been truncated or comprise N- or C-terminal extensions, as well as folded fragments of variable domains which retain at least the binding activity and specificity of the full-length domain. A single variable domain that is capable of binding an antigen or epitope independently of a different variable region or domain may be referred to as a "domain antibody" or "dAb(™)". A single variable domain may be a human single variable domain, but also includes single variable domains from other species such as rodent, nurse shark and Camelid VHH dAbs™. Camelid VHH are immunoglobulin single variable domain polypeptides that are derived from species including camel, llama, alpaca, dromedary, and guanaco, which produce heavy chain antibodies naturally devoid of light chains. Such VHH domains may be humanised according to standard techniques available in the art, and such domains are considered to be "single variable domains". As used herein VH includes camelid VHH domains.
[0045] Alternative antibody formats are those where the CDRs are arranged onto a suitable nonimmunoglobulin protein scaffold or skeleton. The non-immunoglobulin scaffold may be a derived from the group consisting of CTLA-4, lipocalin, Protein A derived molecules such as Z-domain of Protein A (Affibody, SpA), A-domain (Avimer / Maxibody); heat shock proteins such as GroEl and GroES; transferrin (trans-body); ankyrin repeat protein (DARPin); peptide aptamer; C-type lectin domain (Tetranectin); human y-crystal lin and human ubiquitin (affilins); PDZ domains; LDL receptor class A domains; EGF domains; scorpion toxin kunitz type domains of human protease inhibitors; and f i bronecti n / ad necti n .
[0046] Inhibitors of human TRPM3 are known in the art.
[0047] Inhibitors of human TRPM3 include those disclosed in WO2022112345 and WO2022112352. In one embodiment, an inhibitor of human TRPM3 is a compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein:
[0048] R1is selected from the group consisting of: a 4-6 membered saturated heterocyclylic ring, which 4-6 membered heterocyclic ring is optionally substiiuted by one, two or three groups independently selected from oxo, fluoro, Cl- 3fluoroalkyl and C1-3alkyl, which C1-3alkyl group may optionally by substituted by one hydroxy group; and a group of formula -CR6R7CONH2, wherein R6is optionally H or methyl and R7is methyl substituted by one hydroxy group or ethyl substituted by one hyroxy group;
[0049] R2is phenyl or a 5-6 membered nitrogen containing heteroaryl ring, which phenyl or 5-6 membered nitrogen containing heteroaryl ring is optionally substituted by one two or three substituents independently selected from the group consisting of halo, cyclopropyl, cyclopropyloxy, methoxy and Ci-3alkyl, which C1-3alkyl group is optionally substituted by one, two or three substitutents selected from fluoro and cyclopropyl; and
[0050] R3is selected from cycloalkyl and methyl, which methyl group is optionally substituted by one, two or three fluoro groups.
[0051] R4and R5are independently selected from H, or methyl, which methyl group is optionally substituted with a group consisting of hydroxy, methoxy and N(CH3)2.
[0052] In one embodiment, Ri is a group of formula -CR6R7CONH2, wherein R6is optionally H or methyl and R7is methyl substituted by one hydroxy group or ethyl substituted by one hydroxy group. In a more particular embodiment, R1is a group of formula -CH(CH2OH)CONH2.
[0053] In one embodiment, R3is methyl.
[0054] In one embodiment, R4and R5are each H. In another embodiment, R4is H, and R5is methyl, which methyl group is optionally substituted with a group consisting of hydroxy and methoxy. Compounds of formula (I) can be made as described in WO2022112352 or WO2022112345. It will be appreciated that certain compounds of formula (I) may exist in alternative tautomeric forms. For the avoidance of doubt, all tautomers of a compound of formula (I) are encompassed.
[0055] In one embodiment, the inhibitor of human TRPM3 is a compound selected from the group consisting of: 2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3- carboxamide;
[0056] N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide;
[0057] (S)-N-(l-amino-3-hydroxy-l-oxopropan-2-yl)-2-(difluoromethyl)-5-((4-methylthiazol-5- yl)methoxy)benzofuran-3-carboxamide;
[0058] (S)-N-(l-amino-3-hydroxy-l-oxopropan-2-yl)-2-cyclopropyl-5-((4-methylthiazol-5- yl)methoxy)benzofuran-3-carboxamide;
[0059] (S)-5-(benzyloxy)-2-methyl-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide;
[0060] (S)-5-((2-fluorobenzyl)oxy)-2-methyl-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide;
[0061] 5-(benzyloxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide;
[0062] N-(3,3-difluoropiperidin-4-yl)-5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamide;
[0063] (S)-N-(l-amino-l-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3- carboxamide;
[0064] (S)-N-(l-amino-l-oxobutan-2-yl)-5-(benzyloxy)-2-methylbenzofuran-3-carboxamide;
[0065] (S)-N-(l-amino-l-oxobutan-2-yl)-5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamide; (S)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide; 5-(benzyloxy)-2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)benzofuran-3-carboxamide;
[0066] 2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((2-fluorobenzyl)oxy)benzofuran-3-carboxamide;
[0067] (S)-N-(l-amino-3-hydroxy-l-oxopropan-2-yl)-5-(benzyloxy)-2-(difluoromethyl)benzofuran-3- carboxamide;
[0068] (S)-N-(l-amino-3-hydroxy-l-oxopropan-2-yl)-2-(difluoromethyl)-5-((2-fluorobenzyl)oxy)benzofuran-
[0069] 3-carboxamide;
[0070] (S)-2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3- carboxamide;
[0071] (S)-5-(benzyloxy)-2-(difluoromethyl)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide;
[0072] (S)-2-(difluoromethyl)-5-((2-fluorobenzyl)oxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide; (S)-2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide; (S)-5-(benzyloxy)-2-cyclopropyl-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide;
[0073] (S)-2-cyclopropyl-5-((2-fluorobenzyl)oxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide; (S)-N-(l-amino-3-hydroxy-l-oxopropan-2-yl)-5-(benzyloxy)-2-cyclopropylbenzofuran-3- carboxamide; (S)-N-(l-amino-3-hydroxy-l-oxopropan-2-yl)-2-cyclopropyl-5-((2-fluorobenzyl)oxy)benzofuran-3- carboxamide;
[0074] 2-cyclopropyl-N-(3,3-difluoropiperidin-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3- carboxamide;
[0075] 5-(benzyloxy)-2-cyclopropyl-N-(3,3-difluoropiperidin-4-yl)benzofuran-3-carboxamide; and 2-cyclopropyl-N-(3,3-difluoropiperidin-4-yl)-5-((2-fluorobenzyl)oxy)benzofuran-3-carboxamide; or a pharmaceutically acceptable salt thereof.
[0076] Additional inhibitors of human TRPM3 are reviewed in Held et al., (2015, Temperature 2: 201-13). Inhibitors include, for example, primidone (5-ethyldihydro-5-phenyl-4,6(lH,5H)-pyrimidinedione), diclofenac, ononetin, econazole, the calmodulin antagonist W-7, the PPARy agonists rosiglitazone, troglitazone and pioglitazone, the flavonoid derivatives disclosed in Straub et al. (Mol Pharmacol, 2013, 84(5):736-50), the fenamate derivates disclosed in Klose et al.. (Br J Pharmacol., 2011, 162(8): 1757-1769), and the TRPM3-specific polyclonal antibody (TM3E3).
[0077] The properties that define an inhibitor of human TRPM3 are determined experimentally. The skilled person will appreciate that this permits the identification of additional inhibitors of human TRPM3. This is discussed in the section entitled "IDENTIFICATION OF INHIBITORS OF HUMAN TRPM3".
[0078] In particular embodiments, the inhibitor of human TRPM3 exhibits selectivity for inhibition of human TRPM3 channels in comparison to other TRP channels. In particular, the inhibitor of human TRPM3 exhibits selectivity for inhibition of human TRPM3 over one or more of TRPM1, TRPV1, TRPV4 and TRPM8. The skilled person will readily understand that selectivity can be assessed in binding assays for example, an assay using a labelled ligand, or where the TRP channel also acts to increase intracellular calcium, in a calcium mobilisation assay.
[0079] The inhibitor of human TRPM3 may be an inhibitor of a mutated version of human TRPM3, such as those disclosed supra, for example a mutated version of human TRPM3 having a gain of function mutation. For the avoidance of doubt, an inhibitor of a mutated version of human TRPM3 is an inhibitor of the mutated version, and does not require selectivity over the corresponding wild type variant of TRPM3, although selectivity may be required in particular embodiments. For example, in one embodiment, the inhibitor of a mutated version of human TRPM3 having a gain of function mutation is an inhibitor that is selective for the mutated version over the corresponding wild type TRPM3 variant.
[0080] In one embodiment, the inhibitor of human TRPM3 exhibits selectivity for the TRPM3 having the sequence set out in SEQ ID NO: 2 (or a processed version of SEQ ID NO:2 lacking the initial methionine residue) over other TRPM3 variants. Similarly to the above, the skilled person would understand that selectivity for this isoform can be assessed in binding assays or using a calcium mobilisation assay using channels that are homotetra meric for SEQ ID NO:2 (or a processed version of SEQ ID NO:2 lacking the initial methionine residue) and channels that are homotetra meric for the reference TRPM3 variant.
[0081] In a further embodiment, the inhibitor of human TRPM3 selectively inhibits the response to a particular stimulus. As explained in the Background, human TRPM3 is polymodally activated. In one embodiment, inhibition is selective to agonism by pregnenolone sulfate over heat. In another embodiment, inhibition is selective to agonism by pregnenolone sulfate over other agonists e.g., nifedipine, D-erythrosphingosine, CIM2016). A functional assay such as a calcium mobilisation assay may be used to assess selectivity to particular stimuli.
[0082] In the above embodiments in which selectivity is assessed using a binding assay, the Kd for human TRPM3 channels or channels homotetra meric for a particular isoform of human TRPM3 is at least 10 fold lower compared to the reference channel. In a more particular embodiment, the Kd for the human TRPM3 channels or channels homotetra meric for a particular isoform of human TRPM3 is at least 100 fold lower compared to the reference channel. In embodiments above in which selectivity is assessed using a calcium mobilisation assay, the IC50 or Kd derived therefrom for human TRPM3 channels or channels homotetra meric for a particular isoform of human TRPM3 is at least 10 fold lower compared to the reference channel. In a particular embodiment above in which selectivity is assessed using a calcium mobilisation assay, the IC50 or Kd derived therefrom for human TRPM3 channels or channels homotetra meric for a particular isoform of human TRPM3 is at least 100 fold lower compared to the reference channel.
[0083] IDENTIFICATION OF INHIBITORS OF HUMAN TRPM3
[0084] As discussed supra, the properties that define an inhibitor are determined experimentally in assays. These assays can be used to identify additional inhibitors of human TRPM3.
[0085] Property 1 is measured using a calcium mobilisation assay in which changes in intracellular calcium ion levels are detected by changes in calcium indicator compounds. Currently, over one hundred chemically synthesized and genetically encoded calcium indicators are available.
[0086] Accordingly, an inhibitor of human TRPM3 can be identified by a method comprising: a) contacting a cell line expressing human TRPM3 which cells contain an intracellular calcium indicator with an agonist of human TRPM3 in the presence and absence of a test inhibitor; and b) measuring a change in intracellular calcium concentrations by measuring a change in the intracellular calcium indicator; wherein the test inhibitor is identified as an inhibitor for human TRPM3 if intracellular calcium concentrations are reduced in the presence of the test inhibitor compared to those achieved in the absence of test inhibitor.
[0087] In one embodiment, the intracellular calcium indicator is a synthetic calcium indicator, and step a) is preceded by a step of loading the cells with the indicator. Several synthetic calcium indicator compounds are available commercially, for example, the FLUO calcium indicators (Invitrogen). Synthetic calcium indicators may be loaded into cells using methods known in the art. For example, water soluble salts of synthetic calcium indicators may be loaded into cells by well known methods including microinjection, by addition to patch pipette solutions, or by use of pinocytosis, for example using the INFLUX pinocytotic cell loading reagent. Cell permeant AM esters of calcium indicators may be loaded into cells by addition to the media, typically in the presence of a non-ionic detergent such as PLURONIC F-127, and an anion transport inhibitor such as probenecid or sulfinpyrazone, and incubation at 20-37°C for a suitable period of time e.g., between 15 minutes and 4 hours). Following cell loading, cells may be washed and background fluorescence due to indicator leakage could be quenched by addition of, for example, an anti-fluorescein antibody, although this is not essential. Where cell permeant AM esters were used, incubation for a further 30 minutes after loading permits de-esterification of the intracellular AM esters prior to the assay being conducted.
[0088] In an alternative embodiment, the intracellular calcium indicator is a genetically encoded calcium indicator. Several genetically encoded calcium indicators are known in the art, including including the GCaMPs, pericams, GECOs, camgaroos. Constructs for transfecting cell lines with these genetically encoded calcium indicators are known in the art, for example, the GCaMP6s-P2A-Bsr construct (commercially available as Addgene plasmid # 40753). Clonal cell lines based upon this construct showed bright, uniform cytoplasmic staining. Transient and stable cell line production using this construct is described in Wu et al., 2019 (2019, Sci Rep, 9: 12692).
[0089] In one embodiment, DNA encoding the genetically encoded calcium indicator is transfected into a cell line expressing human TRPM3 before step a). In an alternative embodiment, the cell line is a cell line stably expressing the genetically encoded calcium indicator. Calcium mobilisation assays using cells loaded with calcium indicators are well known in the art. In one embodiment, the calcium indicator is an indicator whose fluorescence changes in the presence of calcium ions. In such embodiments, calcium mobilisation assays involve measuring levels of fluorescence following excitation with an appropriate wavelength for the calcium indicator following the addition of an agonist and inhibitor. The inhibitor may be added to the cells either before (e.g. 60 minutes before) or at the same time as the agonist. Fluoresence may be measured using a fluorescent imaging plate reader (several are commercially available, for example FLIPR TETRA), or by FACS analysis. Typically, negative and positive controls and standards are included in each experiment. Negative controls lack agonist, positive controls lack inhibitor and a standard uses a blocking concentration of a known inhibitor, for example, isosakuranetin.
[0090] A suitable calcium mobilisation assay in 96 well plates has been described by Zhao and colleagues, (eLife 2020;9:e55634).
[0091] In a calcium mobilisation assay, an inhibitor of human TRPM3 is a compound that reduces fluorescence emissions compared to the positive control. In various embodiments, the fluorescence is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%. In one embodiment, an inhibitor is a compound that reduces fluorescence by at least as much as a blocking concentration of isosakuranetin. In one embodiment, an inhibitor is a compound that reduces fluorescence by at least as much as a saturating concentration of isosakuranetin (i.e. maximal inhibition with isosakuranetin).
[0092] Property 2 is measured in an electrophysiological assay such as patch clamp or using an automated electrophysiology platform. These assays are well known in the art and several automated electrophysiology platforms are available commercially, for example the IONWORKS platforms, PATCHXPRESS, IONFLUX, QPATCH HT / HTX, PATCHLINER and SYNCHROPATCH platforms.
[0093] Accordingly, an inhibitor of human TRPM3 can be identified by a method comprising measuring the current increases in a cell line expressing human TRPM3 following challenge with an agonist of human TRPM3 in the presence and absence of a test inhibitor, wherein the test inhibitor is identified as an inhibitor for human TRPM3 if the increase in current is reduced in the presence of the test inhibitor compared to the increase achieved in the absence of the test inhibitor.
[0094] In one embodiment, the change in current is measured at a membrane potential of between + / -80mV. In particular embodiments, the change in current is measured at a membrane potential of -80mV, - 70mV, -60mV, -50mV, -40mV, -30mV, -20mV, -lOmV, OmV, +10mV, +20mV, +30mV, +40mV, +50mV, +60mV, +70mV or +80mV. In one embodiment, the change in current is measured at a membrane potential of -80mV. In an alternative ambodiment, the change in current is measured at a membrane potential of +80mV. In certain embodiments, mean changes in current are measured.
[0095] The assays to assess properties 1 and 2 utilise cell lines expressing human TRPM3. Primary or immortalised cell lines endogenously expressing human TRPM3 may be used. In one embodiment, the SHSY-5Y cell line may be used. In another embodiment, transient and stable cell lines expressing recombinant human TRPM3 may be prepared by conventional means. In one embodiment, the invention provides a cell line stably expressing recombinant human TRPM3.
[0096] The production of a HEK293 cell line expressing the human TRPM3 variant i (SEQ ID NO: 11) is described in by Zhao and colleagues supra.. Further cell lines expressing TRPM3 variants are disclosed in WO200526317.
[0097] The assays to assess properties 1 and 2 may be conducted using a cell line expressing a recombinant human TRPM3 variant comprising one or more amino acid substitutions at residues selected from the group consisting of R1670, A1645, R1457, D602, L757, K774, G995, N1114, SI 121, S1678, Y378, V990 and P1090 (numbering based on SEQ ID NO:2). In one embodiment, the cell line expresses a recombinant human TRPM3 variant having one, two or three of the following substitutions R1670Q, A1645V, R1457Q, D602V, L757V, K774R, S1678F, Y378C, V990M / G / L, G995S, N1114D, SI 12 IP and P1090Q (numbering based on SEQ ID NO:2). In one embodiment, the cell line expresses a recombinant human TRPM3 variant comprising the amino acid substitution R1670Q (numbering based on SEQ ID NO:2).
[0098] The assays to assess properties 1 and 2 may be conducted using a cell line expressing recombinant human TRPM3 variant having the sequence set out in SEQ ID NO: 2, a processed version of SEQ ID NO:2 lacking the initial methionine residue, or a variant of SEQ ID NO: 2 or the processed version of SEQ ID NO: 2 comprising one two or three amino acid substitutions compared to the sequence set out in SEQ ID NO:2. In one embodiment, the cell line expresses recombinant human TRPM3 variant having the sequence set out in SEQ ID NO: 2, a processed version of SEQ ID NO:2 lacking the initial methionine, or a variant of SEQ ID NO: 2 or the processed version of SEQ ID NO: 2 which has one, two or three amino acid substitutions at residues selected from the group consisting of R1670, A1645, R1457, D602, L757, K774, S1678, Y378, V990, G995, P1090, N1114 and S1121 (numbering based on SEQ ID NO:2). In one embodiment, the cell line expresses recombinant human TRPM3 varianthaving the sequence set out in SEQ ID NO: 2, a processed version of SEQ ID NO:2, or a variant of SEQ ID NO: 2 or the processed version of SEQ ID NO: 2 which has one, two or three of the following substitutions R1670Q, A1645V, R1457Q, D602V, K774R, L757V, S1678F, Y378C, V990M / G / L, G995S, P1090Q, N1114D and S1121P (numbering based on SEQ ID NO:2). In a more particular embodiment, the cell line is formed by transient transfection of DNA encoding the human TRPM3 varianthaving the sequence set out in SEQ ID NO: 2, a processed version of SEQ ID NO:2 lacking the initial methionine, or a variant of SEQ ID NO: 2 or the processed version of SEQ ID NO: 2 comprising the amino acid substitution R1670Q. In one embodiment, the cell line is formed by transient transfection of DNA encoding the human TRPM3 variant having the sequence set out in SEQ ID NO: 2. In another embodiment, the cell line is formed by transient transfection of DNA encoding the human TRPM3 varianthaving the sequence of SEQ ID NO:2 comprising the amino add substitution R1670Q. In another embodiment, the cell line stably expresses the human TRPM3 varianthaving the sequence set out in SEQ ID NO: 2, a processed version of SEQ ID NO:2 lacking the initial methionine or a variant of SEQ ID NO:2 or the processed version of SEQ ID NO: 2 comprising the amino acid substitution R1670Q. In one embodiment, the cell line stably expresses the human TRPM3 varianthaving the sequence set out in SEQ ID NO: 2 or a processed version of SEQ ID NO: 2 lacking the initial methionine. In one embodiment, the cell line stably expresses the human TRPM3 variant that has the sequence of SEQ ID NO:2 or the processed form of SEQ ID NO:2 lacking the initial methionine, comprising the amino acid substitution R1670Q.
[0099] In further embodiments of the above cell lines, the cell line also stably expresses a genetically encoded calcium indicator. In one embodiment, the cell line is a human cell line. In one embodiment, the assays described above are conducted in this cell line. The cell lines described herein may be used in the identification of an inhibitor of human TRPM3.
[0100] Any compound capable of promoting calcium ion influx in a cell line expressing human TRPM3 may be used as the agonist in the assays described supra. In one embodiment, the influx is mediated by human TRPM3. In one embodiment, the agonist is pregnenolone sulfate or CIM0216 (racemate of 2- (3,4-dihydroquinolin-l(2H)-yl)-AA(5-methylisoxazol-3-yl)-2-phenylacetamide). In a particular embodiment, pregnenolone sulfate is used at a concentration in the range from 1 to 300 pM in the assays measuring properties 1 and 2. In a particular embodiment, pregnenolone sulfate is used at a concentration of about 100 pM in the assays measuring properties 1-4. In another embodiment, CIM0216 is used at a concentration in the range from 0.1 to 30 pM, more particularly in the range from 6 to 10 pM in the assays measuring properties 1 and 2. In one embodiment, CIM0216 or the R or S isomers thereof are used at a concentration of about 6 pM in the assays measuring properties 1 and 2. In another embodiment, CIM0216 or the R or S isomers thereof are used at a concentration of about 10 pM in the assays measuring properties 1 and 2. Property 3 is not unique to inhibitors of human TRPM3 and is a property shared by other anti-epileptic drugs. On its own, property 3 is not capable of identifying inhibitors of human TRPM3.
[0101] THERAPEUTIC USE
[0102] In one aspect, the invention provides an inhibitor of human TRPM3 for use in the treatment of epilepsy, wherein the inhibitor of human TRPM3 is not primidone or a pharmaceutically acceptable salt thereof.
[0103] In another aspect, the invention provides use of an inhibitor of human TRPM3 in the manufacture of a medicament for use in the treatment of epilepsy in a subject, wherein the inhibitor of human TRPM3 is not primidone or a pharmaceutically acceptable salt thereof.
[0104] In a further aspect, the invention provides a method for treating epilepsy in a subject, which method comprises administering to said subject a therapeutically effective amount of an inhibitor of human TRPM3, wherein the inhibitor of human TRPM3 is not primidone or a pharmaceutically acceptable salt thereof.
[0105] In this context, the term "therapeutically effective amount" refers to the quantity of the inhibitor of human TRPM3 that is required for epilepsy treatment. It may vary depending on the compound, the form of epilepsy, and the age and weight of the subject to be treated. Determining therapeutically effective amounts is within the ability of the skilled person.
[0106] In a particular embodiment, the subject is human.
[0107] In one embodiment, epilepsy treatment refers to the treatment of generalized tonic-clonic seizures.
[0108] In one embodiment, the inhibitor of human TRPM3 is used as monotherapy in the treatment of epilepsy. In the context of monotherapy, treatment refers to an increase in the percentage of subjects remaining seizure free for a period of at least six months (excluding the dose titration period).
[0109] In another embodiment, the inhibitor of human TRPM3 is used as adjunctive therapy to another antiepileptic agent. In one embodiment where the inhibitor of human TRPM3 is used as an add on therapy, treatment refers to an increase in the number of patients that achieve a 50% reduction in seizures over a pre-defined period compared to patients receiving monotherapy. In an alternative embodiment, treatment refer to an increase in the proportion of seizure free patients over a predefined period compared to patients receiving monotherapy. In particular embodiments, the predefined period is 4 weeks. When used as adjunctive therapy, the inhibitor of human TRPM3 is administered in combination with at least one other anti-epileptic drug selected from: lamotrigine, levetiracetam and sodium valproate.
[0110] IDENTIFICATION OF PATIENTS FOR TREATMENT
[0111] In one aspect, the invention provides a method for identifying whether a human subject that has epilepsy is a candidate for treatment with an inhibitor of human TRPM3, comprising: a) sequencing a human TRPM3 ene in the human subject; b) comparing the sequence with the sequences of the human TRPM3 exons set out in SEQ ID NOs: 38-69 and identifying whether changes would modify the amino acid sequence of any isoform; wherein, if a change in amino acid sequence is identified, the human subject is a candidate for treatment with an inhibitor of human TRPM3.
[0112] In one embodiment, the changes to the amino acid sequence are selected the group consisting of: D602V, L757V, R1670Q, A1645V, V990M / G / L, G995S, P1090Q, N1114D and SI 12 IP (numbering based on SEQ ID NO: 2). In one embodiment, the change to the amino acid sequence is R1670Q (numbering based on SEQ ID NO: 2).
[0113] In related aspects, the invention provides an inhibitor of human TRPM3 for use in the treatment of epilepsy in a candidate for treatment with an inhibitor of human TRPM3. The invention also provides use of an inhibitor of human TRPM3 for use in the manufacture of a medicament for use in the treatment of epilepsy in a candidate for treatment with an inhibitor of human TRPM3. The invention also provides a method for treating epilepsy in a subject, comprising administering an inhibitor of human TRPM3 to a human subject that is identified as a candidate for treatment with an inhibitor of human TRPM3.
[0114] COMBINATION THERAPY
[0115] The inhibitor of human TRPM3 and any other therapeutic agent(s) may be administered together or separately and, when administered separately, administration may occur simultaneously or sequentially, in any order. The amounts of inhibitor of human TRPM3 of the present invention and the other therapeutic agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. Simultaneous administration may be achieved by administration of (1) a unitary pharmaceutical composition including the therapeutic agents; or (2) simultaneous administration of separate pharmaceutical compositions each including one of the therapeutic agents. Alternatively, the combination may be administered separately in a sequential manner wherein one treatment agent is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time. The amounts of the inhibitor of human TRPM3 of the invention and the other therapeutic agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
[0116] PHARMACEUTICAL COMPOSITIONS / ROUTES OF ADMINISTRATION / DOSAGES
[0117] An inhibitor of human TRPM3 may be administered by any convenient route. In particular embodiments, the inhibitor of human TRPM3 may be administered by orally, parenterally, intranasally or by inhalation. In one embodiment, the inhibitor of human TRPM3 is administered in a pharmaceutical composition. In one embodiment, the inhibitor of human TRPM3 is formulated in a pharmaceutical composition adapted for oral or parenteral administration, or for administration intranasally or by inhalation. Appropriate doses will readily be appreciated by those skilled in the art.
[0118] According to one aspect, the invention provides a pharmaceutical composition comprising an inhibitor of human TRPM3 and a pharmaceutically acceptable excipient. According to another aspect, the invention provides a process for the preparation of a pharmaceutical composition comprising admixing an inhibitor of human TRPM3 with a pharmaceutically acceptable excipient.
[0119] Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
[0120] Pharmaceutical formulations adapted for nasal administration can comprise a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the inhibitor of human TRPM3.
[0121] Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurized aerosols, nebulizers or insufflators. Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and nonaqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
[0122] It should be understood that in addition to the ingredients particularly mentioned above, the formulations described herein may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
[0123] The present disclosure also provides unitary pharmaceutical compositions in which the inhibitor of human TRPM3 one or more other therapeutic agent(s) may be administered together. When an inhibitor of human TRPM3 is used in combination with a second therapeutic agent, the dose of each therapeutic agent may differ from the dose of that therapeutic agent when used alone.
[0124] EXAMPLE
[0125] Example 1 - Maximal Electroshock Seizure Threshold (MEST) Model
[0126] Animals were individually assessed for development of a tonic hind limb extension seizure following a single electrical shock, using an 'up and down method' of shock titration (Kimball AW et al, 1957). The first animal within a treatment group was given a shock at a pre-specified current (see Table 2). For subsequent animals, the stimulus intensity was increased or decreased sequentially as outlined in Table 1 if the preceding animal did or did not show tonic hind limb extension, respectively.
[0127] TABLE 1
[0128] Induction of a seizure by the electrical shock was measured as an all-or-nothing effect scored by the presence (+) or absence (0) of tonic hind limb extensor convulsions for each animal. The data for each group was recorded as the number of +'s and 0's at each current and this information was then used to estimate the CC50 value (current required for 50% of the animals to show seizure behaviour) by fitting a non-parametric model known as centred isotonic regression (Oron and Flournoy, 2017). A non-parametric approach was preferred as it is distribution free and was considered more suitable for the small sample size and limited range of electrical shock tested. To compare CC50 values across groups, analytical 90% confidence intervals of CC50 values were obtained for each group and were then tested for an overlap in pairs, with no overlap suggesting a significant difference. Comparison of 83% confidence intervals is recommended in the literature for small sample size (Oron et al., 2022) and a more conservative approach was taken here with the adoption of 90%. Details on the Binomialbased analytical confidence intervals can be found in Oron and Flournoy (2017), those are readily available in the software used for the analysis (R, version 4.1.1).
[0129] Animals were randomly assigned a number to determine the order of treatment and subsequent electrical shock using a software generated randomisation scheme. Group order was also randomised using the same method. Investigators were not blinded as each group required a different starting current based on a pilot study and the sex of the animals cannot be blinded.
[0130] All animals were intraperitoneally dosed (lOmL / kg) with vehicle (1:1:18 Ethanol: Koi I iphor EL (Cremaphor): physiological saline (0.9% w / v NaCI)) 30 mins prior to electroshock (to mimic compound treatment). Animals were observed following dosing for any adverse effects, and none were observed.
[0131] Animals were shocked via corneal probes applied to both eyes for 0.1 seconds using a Hugo Sachs Electronik stimulator, with an adjustable constant current (1-300 mA). Animals within a group were shocked sequentially before moving to the next group. Following exposure to current and observation of seizure or absence of seizure, animals were concussed by striking the cranium and death confirmed by cervical dislocation. A maximum of 10 seconds of observation was performed before terminating the animal. The starting current values for each group are shown in Table 2.
[0132] TABLE 2
[0133] M Male
[0134] F Female
[0135] WT Wild Type
[0136] KO TRPM3 KO
[0137] In this study, a significant KO effect (no overlap of 90% confidence intervals of KO vs WT groups) was observed with 66% increase in the CC50 estimate for males and 50% increase for females, respectively, based on the centred isotonic regression (CIR) CC50 estimates. Data is shown in Figure 1 and Table 3.
[0138] TABLE 3 SEQUENCE LISTING
[0139] SEQ ID NO: 1: Amino acid sequence of human TRPM3 isoform Xll
[0140] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILAD FiNGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPVVALIVEGGPNVISI VLEYLRDTPPVPWVCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKK ELITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLD RVDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCN YTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKR
[0141] QKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAM KLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDD MPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPI VKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTD LIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMS FGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACY LLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDP DERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQ
[0142] TVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETM SPTSPTLM PRM RSHSFYSVN M KDKGGI EKLESIFKERSLSLH RATSSHSVAKEPKAPAAPANTLAI VPDSRRPSSC IDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDY THLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCID TRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNI TVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFE SKHN
[0143] SEQ ID NO:2: Amino acid sequence of human TRPM3 isoform k
[0144] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDIL AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEE LYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLG MEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKL CKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHR DFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTK EKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKME RWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVI YCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYM
[0145] PYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSIS NQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQ CIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTG LERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDK GGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNIL GLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSK SSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKV EDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRK SFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0146] SEQ ID NO:3: Amino acid sequence of human TRPM3 isoform m MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDIL AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEE LYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLF
[0147] GPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEE AMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNAT CLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQ EKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYL MLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRL QDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEE PSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAV FNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDD
[0148] ELKKVH DFEEQCI EEYFREKDDRFNSSN DERI RVTSERVEN MSM RLEEVN EREHSM KASLQTVDIRLAQLEDLIG RMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRS HSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHC
[0149] DIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDS EPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADR AAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAE EPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0150] SEQ ID N0:4: Amino acid sequence of human TRPM3 isoform X19
[0151] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDIL AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEE LYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRDDIPLRRG RKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEASE NDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQM LLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELT AMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWI VISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYI RLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVF
[0152] ADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQ LIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDR FNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSR TSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKE RSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVP STAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLL EEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREA ELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQR NTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0153] SEQ ID NO: 5: Amino acid sequence of human TRPM3 isoform q
[0154] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE
[0155] CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG
[0156] HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPWVCDGSGRASDIL AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEE LYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLF GPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVAC KLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAK HRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKP TKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVK MERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDG RVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIF YMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKS ISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEE QCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLT
[0157] GLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMK DKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVN ILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIER SKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGD KVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHT RKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0158] SEQ ID NO: 6: Amino acid sequence of human TRPM3 isoform Q9HCF6-6
[0159] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDIL AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEE LYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLG MEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKL CKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHR DFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTK EKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKME RWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVI YCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYM
[0160] PYWMIYGEVFADQIDRKQVYDSHTPKSAPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIA VFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITD DELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLI GRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMR SHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAM DELHC DIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDS EPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADR AAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAE EPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0161] SEQ ID NO:7: Amino acid sequence of human TRPM3 isoform X12
[0162] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPVVALIVEGGPNVISIV LEYLRDTPPVPVWCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKE LITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDR VDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNY TRKRFRTLYHNLFGPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQH GEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWS NATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEI HLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYI
[0163] GYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMI LRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFP NEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNL LIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFI TDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLE DLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMP
[0164] RM RSHSFYSVN M KDKGGI EKLESIFKERSLSLH RATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCI DIYVSAM D ELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNP WDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQA IADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANS YSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0165] SEQ ID NO: 8: Amino acid sequence of human TRPM3 isoform Q9HCF6-8
[0166] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDIL AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGRHGPSNTLYHLVR DVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRDDIPLRRGRKTTKKREEEVDIDLDD PEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSR DFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKN SGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDE EEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILM SEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVM MIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETRED
[0167] GKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIF SHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERV ENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSS FNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAK EPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTD RPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPS RSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAK GRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSS KPEGRGDSLSMRRLSRTSAFQSFESKHN
[0168] SEQ ID NO:9: Amino acid sequence of human TRPM3 isoform s
[0169] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE
[0170] CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG
[0171] HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG
[0172] VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILAD
[0173] NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDIL
[0174] AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK
[0175] GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEE
[0176] LYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLG
[0177] MEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKL
[0178] CKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHR
[0179] DFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTK EKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKME RWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVI YCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYM PYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSIS NQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQ CIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTG LERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPLYSV
[0180] SEQ ID NO: 10: Amino acid sequence of human TRPM3 isoform Q9HCF6-11
[0181] MGKKWRDAAEMERGCSDREDNAESRRRSRSASRGRFAESWKRLSSKQGSTKRSGLPSQQTPAQKSWIERAFY KRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQG GGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFT GGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFIL ADNGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPWALIVEGGPNVIS IVLEYLRDTPPVPVWCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKK KELITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVL DRVDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRC NYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMK RQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLA MKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKD DMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAP IVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVT DLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLM SFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMAC YLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESD PDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASL QTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEET MSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSS CIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSD YTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCI DTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNN ITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSF ESKHN
[0182] SEQ ID NO: 11 Amino acid sequence of human TRPM3 isoform i
[0183] MGKKWRDAAEMERGCSDREDNAESRRRSRSASRGRFAESWKRLSSKQGSTKRSGLPSQQTPAQKSWIERAFY KRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQG GGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFT GGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFIL ADNGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASD ILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALL KGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLE ELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLL GM EDDIPLRRGRKTTKKREEEVDI DLDDPEIN H FPFPFH ELM VWAVLM KRQKM ALFFWQHG EEAM AKALVACK LCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKH
[0184] RDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPT KEKEEEDM ELTAM LGRN NG ESSRKKDEEEVQSKHRLI PLG RKIYEFYN APIVKFWFYTLAYIGYLM LFNYIVLVKM ERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGR VIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFY MPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSI SNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEE QCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLT GLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMK DKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVN ILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIER SKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGD KVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHT RKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0185] SEQ ID NO: 12 Amino acid sequence of human TRPM3 isoform j
[0186] MGKKWRDAAEMERGCSDREDNAESRRRSRSASRGRFAESWKRLSSKQGSTKRSGLPSQQTPAQKSWIERAFY KRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQG GGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFT GGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFIL ADNGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASD ILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALL KGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLE ELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNL FGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGE EAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNA TCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHL QEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGY LMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILR LQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNE EPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIA VFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITD DELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLI GRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPLYSV
[0187] SEQ ID NO: 13 Amino acid sequence of human TRPM3 isoform w
[0188] MGKKWRDAAEMERGCSDREDNAESRRRSRSASRGRFAESWKRLSSKQGSTKRSGLPSQQTPAQKSWIERAFY KRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQG GGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFT GGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFIL ADNGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASD ILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALL KGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLE ELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLL GM EDDIPLRRGRKTTKKREEEVDI DLDDPEIN H FPFPFH ELM VWAVLM KRQKM ALFFWQHG EEAM AKALVACK LCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKH RDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPT KEKEEEDM ELTAM LGRN NG ESSRKKDEEEVQSKHRLI PLG RKIYEFYN APIVKFWFYTLAYIGYLM LFNYIVLVKM ERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGR VIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFY MPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSI SNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEE QCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLT
[0189] GLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPLYSV
[0190] SEQ ID NO: 14 Amino acid sequence of human TRPM3 isoform n
[0191] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDIL AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEE LYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLF GPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEE AMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNAT CLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQ EKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYL
[0192] MLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRL QDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEE PSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAV FNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDD ELKKVH DFEEQCI EEYFREKDDRFNSSN DERI RVTSERVEN MSM RLEEVN EREHSM KASLQTVDIRLAQLEDLIG RMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPLYSV
[0193] SEQ ID NO: 15 Amino acid sequence of human TRPM3 isoform o
[0194] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPVVALIVEGGPNVISIV LEYLRDTPPVPVWCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKE LITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDR VDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIE YLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHE LM VWAVLM KRQKM ALFFWQHG EEAM AKALVACKLCKAM AH EASEN DM VDDISQELN H NSRDFGQLAVELLDQ SYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPS ILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLG
[0195] RKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKV WLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMM YFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKT GAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHL CCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEV NEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFK LQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANT LAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDI TSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPV KTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQE
[0196] GDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSM
[0197] RRLSRTSAFQSFESKHN
[0198] SEQ ID NO: 16 Amino acid sequence of human TRPM3 isoform p MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPVVALIVEGGPNVISIV LEYLRDTPPVPVWCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKE LITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDR VDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIE YLMGGAYRCNYTRKRFRTLYHNLFGPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMK RQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLA MKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKD DMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAP IVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVT DLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLM SFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMAC YLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESD PDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASL QTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPL YSV
[0199] SEQ ID NO: 17 Amino acid sequence of human TRPM3 isoform r
[0200] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDIL AFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLK GANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEE LYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRDDIPLRRG RKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEASE NDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQM LLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELT AMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWI VISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYI RLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLVVLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVF
[0201] ADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQ LIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDR FNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSR TSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPLYSV SEQ ID NO: 18 Amino acid sequence of human TRPM3 isoform t
[0202] MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPVVALIVEGGPNVISIV LEYLRDTPPVPVWCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKE LITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDR VDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIE YLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHE LMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQ SYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPS ILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLG RKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKV WLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMM YFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKT GAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHL CCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEV NEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFK
[0203] LQESIDPAEHPLYSV
[0204] SEQ ID NO: 19 Amino acid sequence of human TRPM3 isoform v
[0205] MYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVI RHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGK YGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDILAFGHKYS EEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLKGANASAP DQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHG PSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKA LKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALV ACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVA AKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEP EKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIV LVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFR SDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLA KNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFF EVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVH DFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATAL ERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPLYSV
[0206] SEQ ID NO: 20 Amino acid sequence of human TRPM3 isoform a
[0207] MYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVI RHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGK YGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDILAFGHKYS EEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLKGANASAP DQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHG PSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPL RRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHE ASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTC SQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEED MELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPST QEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNII YWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMI YGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWK FQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFR EKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAES NKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKL ESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPS FSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLA TTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCC HPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDK LDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0208] SEQ ID NO: 21 Amino acid sequence of human TRPM3 isoform b
[0209] MYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVI RHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGK YGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDILAFGHKYS EEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLKGANASAP DQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHG PSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKA LKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALV ACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVA AKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEP EKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIV LVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFR SDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLA KNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFF EVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVH DFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATAL ERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSV NMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLD NSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMY HTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPG GLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAP YAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0210] SEQ ID NO: 22 Amino acid sequence of human TRPM3 isoform d
[0211] MYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVI RHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGK YGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDILAFGHKYS EEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLKGANASAP DQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHG PSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRDDIPLRRGRKTTKKR EEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDI SQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMW MGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRN NGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTL GIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFG VNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDP PCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFH ERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSN DERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDC TDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSL HRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPS SSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPI VKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSH PSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTAS LRN PFQRSKSSKPEGRGDSLSM RRLSRTSAFQSFESKH N
[0212] SEQ ID NO: 23 Amino acid sequence of human TRPM3 isoform e
[0213] MYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVI RHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGK YGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDILAFGHKYS EEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLKGANASAP DQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHG PSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRDDI PLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMA HEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAH TCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEE DM ELTAM LG RN NGESSRKKDEEEVQSKH RLIPLGRKIYEFYN API VKFWFYTLAYIGYLM LFN YIVLVKM ERWPS TQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVN IIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWM IYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVW KFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYF REKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAE SNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEK LESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEP SFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYL ATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTC CHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISD KLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0214] SEQ ID NO: 24 Amino acid sequence of human TRPM3 isoform f
[0215] MYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVI RHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGK YGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPWALIVEGGPNVISIVLEYLRDT PPVPVWCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRM GSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLL IENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRT LYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFF WQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELK NWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQ AQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYT LAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFS VGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQA ILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILL VNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGL KLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLA QLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTL M PRM RSHSFYSVN M KDKGGI EKLESIFKERSLSLH RATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSA
[0216] MDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPEC QNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNA PQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIER ANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0217] SEQ ID NO:25 Amino acid sequence of human TRPM3 isoform g
[0218] MYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVI RHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGK YGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPWALIVEGGPNVISIVLEYLRDT PPVPVWCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRM GSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLL IENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRT LYHNLFGPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMA KALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQ LAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKE AEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLF NYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQD QPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPS WKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFN NTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDEL
[0219] KKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGR MATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSH SFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDI DPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEP PMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAA FPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEP SAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0220] SEQ ID NO: 26 Amino acid sequence of human TRPM3 isoform X18
[0221] MGKKWRDAAEMERGCSDREDNAESRRRSRSASRGRFAESWKRLSSKQGSTKRSGLPSQQTPAQKSWIERAFY KRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQG GGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFT GGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFIL ADNGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASD ILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALL KGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLE ELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRDDIPLRR GRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEAS ENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQ MLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMEL TAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEW IVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWY IRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEV FADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRY QLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDD RFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRS RTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFK ERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPV PSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFL LEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPERE AELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQ
[0222] RNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0223] SEQ ID NO: 27 Amino acid sequence of human TRPM3 isoform X15
[0224] MGKKWRDAAEMERGCSDREDNAESRRRSRSASRGRFAESWKRLSSKQGSTKRSGLPSQQTPAQKSWIERAFY KRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQG GGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFT GGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFIL ADNGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASD ILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALL KGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLE ELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNL FGPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVA CKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAA KHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPE KPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVL VKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRS DGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAK NIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFE VKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHD FEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALE RLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVN
[0225] MKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNS VNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTI ERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLG DKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAH
[0226] TRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0227] SEQ ID NO: 28 Amino acid sequence of human TRPM3 isoform X13
[0228] MGKKWRDAAEMERGCSDREDNAESRRRSRSASRGRFAESWKRLSSKQGSTKRSGLPSQQTPAQKSWIERAFY KRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQG GGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFT GGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFIL ADNGTTGKYGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASD ILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALL KGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLE ELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNL FGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGE EAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNA TCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHL QEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGY LMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILR LQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNE EPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIA VFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITD DELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLI
[0229] GRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMR SHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAM DELHC DIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDS EPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADR AAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAE EPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0230] SEQ ID NO: 29 Amino acid sequence of human TRPM3 isoform X10
[0231] M PEP WGTVYFLGIAQVFSFLFSWWN LEGVM NQADAPRPLN WTIRKLCH AAFLPSVRLLKAQKSWI ERAFYKRE CVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGG HSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGG VNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILAD NGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPVVALIVEGGPNVISIV LEYLRDTPPVPVWCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKE LITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDR VDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIE YLMGGAYRCNYTRKRFRTLYHNLFGPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMK RQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLA MKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKD DMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAP IVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVT DLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLM SFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMAC YLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESD PDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASL QTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEET MSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSS CIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSD YTHLPECQN PWDSEPPMYHTI ERSKSSRYLATTPFLLEEAPI VKSHSFM FSPSRSYYAN FGVPVKTAEYTSITDCI DTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNN ITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSF ESKHN
[0232] SEQ ID NO: 30 Amino acid sequence of human TRPM3 isoform X4
[0233] MGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVK LLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRF RTLYHNLFGPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEA MAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATC LQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQE KEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLM LFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQ DQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEP SWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVF NNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDE LKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGR MATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSH SFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDI DPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEP PMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAA FPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEP
[0234] SAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0235] SEQ ID NO: 31 Amino acid sequence of human TRPM3 isoform X7
[0236] MGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVK LLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRF RTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALF FWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYEL KNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMS QAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWF YTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILL FSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVAR QAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVAN ILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDY GLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIR LAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPLYSV
[0237] SEQ ID NO: 32 Amino acid sequence of human TRPM3 isoform X3
[0238] MGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVK LLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRF RTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALF FWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYEL KNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMS QAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWF YTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILL FSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVAR QAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVAN ILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDY GLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIR LAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSP TLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYV
[0239] SAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLP ECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCV NAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKI ERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0240] SEQ ID NO: 33 Amino acid sequence of human TRPM3 isoform X6
[0241] MGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVK LLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGG AYRCNYTRKRFRTLYHNLFGPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMA LFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTY ELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYM SQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFW FYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAIL LFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVA RQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVA NILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERD YGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDI
[0242] RLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAEHPLYSV
[0243] SEQ ID NO: 34 Amino acid sequence of human TRPM3 isoform X2
[0244] MGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVK LLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGG AYRCNYTRKRFRTLYHNLFGPKRDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMA LFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTY ELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYM SQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFW FYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAIL LFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVA RQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVA NILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERD YGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDI
[0245] RLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTS PTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIY VSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHL PECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRC VNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVP KIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESK HN
[0246] SEQ ID NO: 35 Amino acid sequence of human TRPM3 isoform X5
[0247] MGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVK LLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGG AYRCNYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWA VLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQD EQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEF KNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYE FYN API VKFWFYTLAYIGYLM LFNYIVLVKM ERWPSTQEWIVISYI FTLGIEKM REI LMSEPGKLLQKVKVWLQEY WNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIML WLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPA IMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRK HESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHS MKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDP AEHPLYSV
[0248] SEQ ID NO: 36 Amino acid sequence of human TRPM3 isoform XI
[0249] MGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVK LLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKREYPGFGWIYFKGNLPPDYRISLIDIGLVIEYLMGG AYRCNYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWA VLM KRQKM ALFFWQHGEEAM AKALVACKLCKAM AH EASEN DM VDDISQELN HN SRDFGQLAVELLDQSYKQD EQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEF KNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYE FYNAPIVKFWFYTLAYIGYLM LFNYIVLVKM ERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEY WNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIML WLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPA IMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRK HESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHS MKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDP AGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDS RRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTR SFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTS ITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSER TLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTS AFQSFESKHN
[0250] SEQ ID NO: 37 Amino acid sequence of human TRPM3 isoform A2A3F3
[0251] MYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVI RHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDWRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGK YGAEVKLRRQLEKHISLQKINTRIGQGVPWALIVEGGPNVISIVLEYLRDTPPVPVWCDGSGRASDILAFGHKYS EEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLKGANASAP DQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHG PSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPL
[0252] RRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHE ASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTC
[0253] SQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEED MELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPST
[0254] QEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNII YWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLWLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMI YGEVFADQIDRKQVYDSHTPKSAPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTF FEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKV HDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMAT ALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFY SVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPL DNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPM YHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFP
[0255] GGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSA PYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
[0256] SEQ ID NO: 38 Nucleotide sequence of exon 1 of the human TRPM3 gene
[0257] GGCAAAGGCAGCGCCAACCGAGAGCCGCGCGCAGGCTGGAGGGAGACCCGCGGCGAGGAGCCAGCGAGAG CGCTCGGCGCTGGGCTGTTTCCCGGCCGAGGGAGGCGAACTTCTCATGGGGAAGAAGTGGAGGGATGCGGC
[0258] GGAAATGGAGCGGGGCTGCTCCGACCGCGAGGACAACGCGGAGAGCCGCAGACGCAGCCGGAGCGCCAGCC GGGGCAGGTTTGCCGAGTCGTGGAAAAGGTTAAGTTCCAAGCAGGGGTCCACCAAACGCTCGGGACTCCCG TCGCAGCAGACGCCG
[0259] SEQ ID NO: 39 Nucleotide sequence of exon 2 of the human TRPM3 gene
[0260] ATTCTGGAGCAGGCTGCTTTGACTCCGACCACAGGCTGTTTTGTGCAGGCTGTCCCTCTTCTTCAAAATCGT GCATCCCCTCCCCGAAGCAGCAGGCAGTGTGCCTCCATTCAGCCACATTTGGTATGCATGAGCACGGCTGCA GAGAGAGGGGAGGTGGCTGTTTTAAGAAGGTTCAGGGGCTCAGGCAAGGCTACTTGACTAGTCTTCCAAGT TCCAGGAAGCCTCTGCCCTAATGGAATTTGCAGGTGTGGAGATGACCATGGGATGCCAGAGCCGTGGGGGA CCGTTTATTTTCTAGGCATTGCTCAGGTTTTCAGTTTCTTGTTTTCCTGGTGGAATTTGGAAGGGGTCATGA ATCAGGCTGATGCTCCTCGACCCCTAAACTGGACCATCCGGAAGCTGTGCCACGCAGCCTTTCTTCCATCTGT CAGACTTCTGAAG
[0261] SEQ ID NO: 40 Nucleotide sequence of exon 3 of the human TRPM3 gene
[0262] AGCAAAATGAAAGCAACAGGAGCTGCTCCGGGGACTGCTTTTGCCAGTACCCAGAATCAGTGCTCAG
[0263] SEQ ID NO: 41 Nucleotide sequence of exon 4 of the human TRPM3 gene
[0264] GCTCAGAAATCCTGGATAGAAAGAGCATTTTATAAAAGAGAATGTGTCCACATCATACCCAGCACCAAAGACC CCCATAG
[0265] SEQ ID NO: 42 Nucleotide sequence of exon 5 of the human TRPM3 gene GTGTTGCTGTGGGCGTCTGATAGGCCAGCATGTTGGCCTCACCCCCAGTATCTCCGTGCTTCAGAATGAGAA AAATGAAAGTCGCCTCTCCCGAAATGACATCCAGTCTGAAAAGTGGTCCATCAGCAAACACACTCAACTCAGC CCTACGGATGCTTTTGGGACCATTGAGTTCCAAGGAGGTGGCCATTCCAACAAAGCCATG
[0266] SEQ ID NO: 43 Nucleotide sequence of exon 6 of the human TRPM3 gene
[0267] TATGTGCGAGTATCTTTTGATACAAAACCTGATCTCCTCTTACACCTGATGACCAAGGAATGGCAGTTGGAG
[0268] CTTCCCAAGCTTCTCATCTCTGTCCATGGGGGCCTGCAGAACTTTGAACTCCAGCCAAAACTCAAGCAAGTCT
[0269] TTGGGAAAGGGCTCATCAAAGCAGCAATGACAACTGGAGCGTGGATATTCACTGGAGGGGTTAACACAG
[0270] SEQ ID NO: 44 Nucleotide sequence of exon 7 of the human TRPM3 gene
[0271] GTGTTATTCGTCATGTTGGCGATGCCTTGAAGGATCATGCCTCTAAGTCTCGAGGAAAGATATGCACCATAG
[0272] GTATTGCCCCCTGGGGAATTGTGGAAAACCAGGAGGACCTCATTGGAAGAGAT
[0273] SEQ ID NO: 45 Nucleotide sequence of exon 8 of the human TRPM3 gene
[0274] GTTGTCCGGCCATACCAGACCATGTCCAATCCCATGAGCAAGCTCACTGTTCTCAACAGCATGCATTCCCACT
[0275] TCATTCTGGCTGACAACGGGACCACTGGAAAATATGGAGCAGAGGTGAAACTTCGAAGACAACTGGAAAAGC ATATTTCACTCCAGAAGATAAACACAA
[0276] SEQ ID NO: 46 Nucleotide sequence of exon 9 of the human TRPM3 gene
[0277] GATGCCTGCCGTTTTTCTCTCTTGACTCCCGCTTGTTTTATTCATTTTGGGGTAGTTGCCAGTTAGACTCAGT TG
[0278] SEQ ID NO: 47 Nucleotide sequence of exon 10 of the human TRPM3 gene
[0279] GAATCGGTCAAGGTGTTCCTGTGGTGGCACTCATAGTGGAAGGAGGACCCAATGTGATCTCGATTGTTTTGG
[0280] AGTACCTTCGAGACACCCCTCCCGTGCCAGTGGTTGTCTGTGATGGGAGTGGACGGGCATCGGACATCCTG GCCTTTGGGCATAAATACTCAGAAGAAGGCGG
[0281] SEQ ID NO: 48 Nucleotide sequence of exon 11 of the human TRPM3 gene
[0282] ACTGATAAATGAATCTTTGAGGGACCAGCTGTTGGTGACTATACAGAAGACTTTCACATACACTCGAACCCAA GCTCAGCATCTGTTCATCATCCTCATGGAGTGCATGAAGAAGAAGGAATTG
[0283] SEQ ID NO: 49 Nucleotide sequence of exon 11a of the human TRPM3 gene
[0284] GCAGAATCTCACCAGGCCTGCCTAAACTACCCATCCCTGGCTGACCTCAGTGCCCCCTAGTCTCTCCATTCCA
[0285] GTTGAAACAGGACAGCTGGATGACTCCCATTAAGGAGCAACTCTCATAATGTAACCTCCCACCCAATCGGAAA CCCACATTACCCTCGCTGTGCTTCCCAAG
[0286] SEQ ID NO: 50 Nucleotide sequence of exon 12 of the human TRPM3 gene
[0287] ATTACGGTATTTCGGATGGGATCAGAAGGACACCAGGACATTGATTTGGCTATCCTGACAGCTTTACTCAAA G
[0288] SEQ ID NO: 51 Nucleotide sequence of exon 13 of the human TRPM3 gene
[0289] GAGCCAATGCCTCGGCCCCAGACCAACTGAGCTTAGCTTTAGCCTGGAACAGAGTCGACATCGCTCGCAGCC AGATCTTTATTTACGGGCAACAGTGGCCG
[0290] SEQ ID NO: 52 Nucleotide sequence of exon 14 of the human TRPM3 gene GTGGGATCTCTGGAGCAAGCCATGTTGGATGCCTTAGTTCTGGACAGAGTGGATTTTGTGAAATTACTCATA GAGAATGGAGTAAGCATGCACCGTTTTCTCACCATCTCCAGACTAGAGGAATTGTACAATACG
[0291] SEQ ID NO: 53 Nucleotide sequence of exon 15 of the human TRPM3 gene AGACATGGGCCCTCAAATACATTGTACCACTTGGTCAGGGATGTCAAAAAG
[0292] SEQ ID NO: 54 Nucleotide sequence of exon 16 of the human TRPM3 gene CGAGAGTATCCAGGTTTCGGTTGGATCTATTTTAAG
[0293] SEQ ID NO: 55 Nucleotide sequence of exon 17 of the human TRPM3 gene
[0294] GGGAACCTGCCCCCAGACTACAGAATCAGCCTGATTGACATCGGCCTGGTGATCGAGTACCTGATGGGCGG
[0295] GGCTTATCGCTGCAACTACACGCGCAAGCGCTTCCGGACCCTCTACCACAACCTCTTCGGCCCCAAGAGG
[0296] SEQ ID NO: 56 Nucleotide sequence of exon 18 of the human TRPM3 gene CCCAAAGCCTTGAAACTGCTGGGAATGGAG
[0297] SEQ ID NO: 57 Nucleotide sequence of exon 19 of the human TRPM3 gene
[0298] GATGATATTCCCTTGAGGCGAGGAAGAAAGACAACCAAGAAACGTGAAGAAGAGGTGGACATTGACTTGGAT
[0299] GATCCTGAGATCAACCACTTCCCCTTCCCTTTCCATGAGCTCATGGTGTGGGCTGTTCTCATGAAGCGGCAG
[0300] AAGATGGCCCTGTTCTTCTGGCAGCACGGTGAGGAGGCCATGGCCAAGGCCCTGGTGGCCTGCAAGCTCTG
[0301] CAAAGCCATGGCTCATGAGGCCTCTGAGAACGACATGGTTGACGACATTTCCCAGGAGCTGAATCACAATTC CAG
[0302] SEQ ID NO: 58 Nucleotide sequence of exon 20 of the human TRPM3 gene
[0303] AGACTTTGGCCAGCTGGCTGTGGAGCTCCTGGACCAGTCCTACAAGCAGGACGAACAGCTGGCCATGAAACT
[0304] GCTGACGTATGAGCTGAAGAACTGGAGCAACGCCACGTGCCTGCAGCTTGCCGTGGCTGCCAAACACCGCGA
[0305] CTTCATCGCGCACACGTGCAGCCAGATGCTGCTCACCGACATGTGGATGGGCCGGCTCCGCATGCGCAAGAA CTCAGGCCTCAAG
[0306] SEQ ID NO: 59 Nucleotide sequence of exon 21 of the human TRPM3 gene
[0307] GTAATTCTGGGAATTCTACTTCCTCCTTCAATTCTCAGCTTGGAGTTCAAGAACAAAGACGACATGCCCTATA
[0308] TGTCTCAGGCCCAGGAAATCCACCTCCAAGAGAAGGAGGCAGAAGAACCAGAGAAGCCCACAAAGGAAAAAG AGGAAGAGGACATGGAGCTCACA
[0309] SEQ ID NO: 60 Nucleotide sequence of exon 22 of the human TRPM3 gene
[0310] GCAATGTTGGGACGAAACAACGGGGAGTCCTCCAGGAAGAAGGATGAAGAGGAAGTTCAGAGCAAGCACCG
[0311] GTTAATCCCCCTCGGCAGAAAAATCTATGAATTCTACAATGCACCCATCGTGAAGTTCTGGTTCTACACA
[0312] SEQ ID NO: 61 Nucleotide sequence of exon 23 of the human TRPM3 gene
[0313] CTGGCGTATATCGGATACCTGATGCTCTTCAACTATATCGTGTTAGTGAAGATGGAACGCTGGCCGTCCACC
[0314] CAGGAATGGATCGTAATCTCCTATATTTTCACCCTGGGAATAGAAAAGATGAGAGAG
[0315] SEQ ID NO: 62 Nucleotide sequence of exon 24 of the human TRPM3 gene
[0316] ATTCTGATGTCAGAGCCAGGGAAGTTGCTACAGAAAGTGAAGGTATGGCTGCAGGAGTACTGGAATGTCAC
[0317] GGACCTCATCGCCATCCTTCTGTTTTCTGTCGGAATGATCCTTCGTCTCCAAGACCAGCCCTTCAGGAGTGAC GGGAGGGTCATCTACTGCGTGAACATCATTTACTGGTATATCCGTCTCCTAGACATCTTCGGCGTGAACAAG
[0318] TATTTGGGCCCGTATGTAATGATGATTGGAAAAATG
[0319] SEQ ID NO: 63 Nucleotide sequence of exon 25 of the human TRPM3 gene
[0320] ATGATAGACATGATGTACTTTGTCATCATTATGCTGGTGGTTCTGATGAGCTTTGGGGTCGCCAGGCAAGCC
[0321] ATCCTTTTTCCCAATGAGGAGCCATCATGGAAACTGGCCAAGAACATCTTCTACATGCCCTATTGGATGATTT
[0322] ATGGGGAAGTGTTTGCGGACCAGATAGACC
[0323] SEQ ID NO: 64 Nucleotide sequence of exon 26 of the human TRPM3 gene
[0324] CTCCCTGTGGACAGAATGAGACCCGAGAGGATGGTAAAATAATCCAGCTGCCTCCCTGCAAGACAGGAGCTT
[0325] GGATCGTGCCGGCCATCATGGCCTGCTACCTCTTAGTGGCAAACATCTTGCTGGTCAACCTCCTCATTGCTG
[0326] TCTTTAA
[0327] SEQ ID NO: 65 Nucleotide sequence of exon 27 of the human TRPM3 gene
[0328] CAATACATTTTTTGAAGTAAAATCGATATCCAACCAAGTCTGGAAGTTTCAGAGGTATCAGCTCATCATGACT
[0329] TTCCATGAAAGGCCAGTTCTGCCCCCACCACTGATCATCTTCAGCCACATGACCATGATATTCCAGCACCTGT
[0330] GCTGCCGATGGAGGAAACACGAGAGCGACCCGGATGAAAGGGACTACGGCCTGA
[0331] SEQ ID NO: 66 Nucleotide sequence of exon 28 of the human TRPM3 gene
[0332] AACTCTTCATAACCGATGATGAGCTCAAGAAAGTACATGACTTTGAAGAGCAATGCATAGAAGAATACTTCAG
[0333] AGAAAAGGATGATCGGTTCAACTCATCTAATGATGAGAGGATACGGGTGACTTCAGAAAG
[0334] SEQ ID NO: 67 Nucleotide sequence of exon 29 of the human TRPM3 gene
[0335] GGTGGAGAACATGTCTATGCGGCTGGAGGAAGTCAACGAGAGAGAGCACTCCATGAAGGCTTCACTCCAGA
[0336] CCGTGGACATCCGGCTGGCGCAGCTGGAAGACCTTATCGGGCGCATGGCCACGGCCCTGGAGCGCCTGACA
[0337] GGTCTGGAGCGGGCCGAGTCCAACAAAATCCGCTCGAGGACCTCGTCAGACTGCACGGACGCCGCCTACATT
[0338] GTCCGTCAGAGCAGCTTCAACAGCCAGGAAGGGAACACCTTCAAGCTCCAAGAGAGTATAGACCCTGCAGGT
[0339] GAGGAGACCATGTCCCCAACTTCTCCAACCTTAATGCCCCGTATGCGAAGCCATTCTTTCTATTCGGTCAATA
[0340] TGAAAGACAAAGGTGGTATAGAAAAGTTGGAAAGTATTTTTAAAGAAAGGTCCCTGAGCCTACACCGGGCTA
[0341] CTAGTTCCCACTCTGTAGCAAAAGAACCCAAAGCTCCTGCAGCCCCTGCCAACACCTTGGCCATTGTTCCTGA
[0342] TTCCAGAAGACCATCATCGTGTATAGACATCTATGTCTCTGCTATGGATGAGCTCCACTGTGATATAGACCCT
[0343] CTGGACAATTCCGTGAACATCCTTGGGCTGGGCGAGCCAAGCTTTTCAACTCCAGTACCTTCCACAGCCCCTT
[0344] CAAGTAGTGCCTATGCAACACTTGCACCCACAGACAGACCTCCAAGCCGGAGCATTGATTTTGAGGACATCA
[0345] CCTCCATGGACACTAGATCTTTTTCTTCAGACTACACCCACCTCCCAGAATGCCAAAACCCCTGGGACTCAGA
[0346] GCCTCCGATGTACCACACCATTGAGCGTTCCAAAAGTAGCCGCTACCTAGCCACCACACCCTTTCTTCTAGAA
[0347] GAGGCTCCCATTGTGAAATCTCATAGCTTTATGTTTTCCCCCTCAAGGAGCTATTATGCCAACTTTGGGGTGC
[0348] CTGTAAAAACAGCAGAATACACAAGTATTACAGACTGTATTGACACAAGGTGTGTCAATGCCCCTCAAGCAAT
[0349] TGCGGACAGAGCTGCCTTCCCTGGAGGTCTTGGAGACAAAGTGGAGGACTTAACTTGCTGCCATCCAGAGCG
[0350] AGAAGCAGAACTGAGTCACCCCAGCTCTGACAGTGAGGAGAATGAGGCCAAAGGCCGCAGAGCCACCATTGC
[0351] AATATCCTCCCAGGAGGGTGATAACTCAGAGAGAACCCTGTCCAACAACATCACTGTTCCCAAGATAGAGCG
[0352] CGCCAACAGCTACTCGGCAGAGGAGCCAAGTGCGCCATATGCACACACCAGGAAGAGCTTCTCCATCAGTGA
[0353] CAAACTCGACAGGCAGCGGAACACAGCAAGCCTGCGAAATCCCTTCCAGAGAAGCAAGTCCTCCAAGCCGGA
[0354] GGGCCGAGGGGACAGCCTGTCCATGAGGAGACTGTCCAGAACATCGGCTTTCCAAAGCTTTGAAAGCAAGCA
[0355] CAACTAAACCTTCTTAATATCCGCCACAGAAGGCTCAAGAATCCAGCCCTAAAATTCTCTCCAACTCCAGTTT
[0356] TTCCCCTTTCCTTGAATCATACCTGCTTTATTCTTAGCTGAGCAAAACAAGCAATGCTTTGGGAGGTGTTAAC TCAAAGGTGACTTCTGGGCCACAGATCAAGAAAGCATTTGATCTGACCCAGTGCCAGACACAGGGGATTTAA
[0357] GGCATGTTCACACTTGCTGGGCAGGGAGGGGGAAGAGAGGGAGAAGGAAGGGTTAGAGATGAATGTGTATC
[0358] CGCAGTCACAGCAGAAAGCCATGAGAGCAGGGGAAACAAGGGGCTTCGAGCACGCTCCATGCCAGGAGGCA
[0359] TCTGTTGATTTCTGACCATTATCAAGAGTTGTAGGATGCAGGGCTAAATTGCAAAATAAAATAAAATAGCCAG
[0360] CGTACACAATGAGATATTCTAAACTTCCATTCTGTTTTCTTTTCACATTGGCTCCATCACTGGTGACTGATGA
[0361] AGAGCATCCTCTTTATTCAGTATAAGCCGGCAGCAAGCAGTTCTACCTAACGTCCCACATCCTTCTCATGCCA
[0362] ACACTTCTGTAATTGATCATTATAAAGAAAAAACAAGGTAACAGTCATAGTTCACCTGTCTCTTATCTATTCA
[0363] CTTCTGGTGCCACAACTGTTTATCCTTTTTTGAAGAAAATAAGGGAACAGAAATGCCTTTTTGTATTGCAATC
[0364] GAAATGAAAGAAGAGTTGATGTTAAAAAAACAAAAGTCAAGTGATTTATTATATACAGTGGGCGTTCAAGTC
[0365] TAGTCGAGCAAGCTCAGGAGAATGTAATTAAATAATTTTATATTTTTTAATTTATTTTGTATCTCACCTGTCA
[0366] TGGATGAATTCATTCACTGAATATGTAATATTGAACTTAAAAAAAAAAAAAAAAAAACAGTGGACAGAACTAG
[0367] CCTGAAATTGCCATGTGGGATGTTCTGTTCTCACCGTTCATGTCGTGTGTTGTGCTGCTGTGTGACCGTCAT
[0368] CATTTGCATGGCTCCACCACGTCCTCCTGAACACCTCCAAGACGTAACTGCCAATTTTTCACACCACTCATCA
[0369] CATGACCATTTTGTATATGAATATATGGTTATATGTGGATATTTTCATACCTAGAGTTTTGCCATCTAATCTG
[0370] AGCTCAGCATAAATTTAATTGGAGTTTTTCAAGGGCTGGTATCTTTTCTATGGAAATGTTCCAAAGTACTTTT
[0371] TAAGGAAGTTTCAAAACTATAAATAACCTTAGATTTGACTGGGAGTTTGGTATCAACCCAAAGCCATCAGTTG
[0372] CAAGCATACCATGAATATTTTTCTTATAGACAGAGCTATAAAAAAAGATACAGTAGACCAAAATAGAAAGCAA
[0373] ATAAACCATATAAAGAGTTCTATAGTATATGCCACTTATACACATGTATATGCATTTATGCAGAGACACATAT
[0374] TTATATATAAAATAAATGGACATAAAGAGCTTTCTTAAGAGGCTTGGACTTTTCTATCACCTTGAAGTATAAT
[0375] CAAGATTTTTTTTAATATACAAGAAGTTCCATTGAAAGAGTTCATTATACTATTAGACCAAATGTTGAAATTA
[0376] TGAATTTTTTAAATTCCTATGACTTTTCCTCATATCAAACTAGAGTTGTCAAAATGACTCACTGCTCGCCTTCT
[0377] GCCCTTTTTTGTCTGAAATCACTCACTATCAGGACATCTCATTTAGTCTCGCTTTTCCTAAACAAAGTTTTTAC
[0378] ACCACGTACAATCTGAATAGACACGCAACTTTAAACCAGCTAGTGTTACAGACTCTAAAGTAGAGGCATAATC
[0379] TTCTAGATCAGAATCTGGATTGGAAGTGGGATAAAGAAATCTTGACCCCAAATCTTTGGATTCCTATTTGGCT
[0380] CATTAACGTTTAAAAAAGAATAAAGCCTTTAAGGAAAACAATCTATTGTTCCTGGCCTGAGATACTACCTGGT
[0381] TCTTTTGTTTAATTATAATTGAAAACACCAAGTTTTACTTTATTTTGTGAAATCAAGTAAATACATGGCCTTTA
[0382] AATATAAGATAAAAAACAAAATAAAAACTCTTCTGAATAAGCATTTCAGGTATAAAAATTGTGATGAGGTCAC
[0383] ATATGTAAAGAATTAAACAATTCCTTTTTCACTCCTTGGCATTTAGGTGAATTGCTAACAAACACCCAGACTC
[0384] CCTTATTTACAGCTGTTCTAGAAACACTTAACATTTTATTGGGCCCCACGCTGGCTATTTCCCTCTCAGCAAA
[0385] CATGCACTGGGTCTGAGAATAAATCAGTCGTTCTTAAACTTCCTTGAGTCATGAATCCCTACGAGGCTCTACG
[0386] ATAACTCTAGGCTCTCTCTCCAGAAAGAAAAAAAAAATGTACATAATGCAAAGTTGCAATATAACTTGAAAGG
[0387] GTTCATGAGCCCCTGGTTCTATATTGATTATGAGGGAAAGGAACCATGTTTGCTCGTAGTTAATGCAGTTGT
[0388] AATAGGCACTTTACATTTGAGACCATCTCTCTGTGATTCTCAGGAAGGCCAAATCTCAGCACCAGAGTTTGAA
[0389] CAAAGATTTTGTTATTTTTGTTCTTTAAATTAGATGTTGCCAATTTAATGCACTTACATCCTAACATGTTGAT
[0390] GATTTTAAGTATCAAGCACAATCACAATGCTGAAGTCTCCCTGAAGGGTCTATAGAGGAATCCAAGAAGGAG
[0391] GTGAAAACATTATTCATTGACATCAAACACCTCCAAGGCCTCATTCTGGGCCAGATTGGAAGTGAGGGAAAG
[0392] AAATTTTCAGCTCAAGTGTTTCCATTCATCGTGATTTCAGAGAGAAAAGGATAGGAACTGGGAAACGAAATA
[0393] CTCAACAGTCCTGATCTTGCAATTACCTGATTCTTTTGTTGTGCATGAAAATTAAGTTCTAACGTCTGTGAAA
[0394] CGTGTGAAATATATAAGCCAAACTTAAATGACTGTAGACACAAACTGTGTAACTTCCATGAGCCATTTCCTTC
[0395] CTGTGCACATGTATGTGTGTTATTTTTCAGTCCATTTCCTTCCATTTCTGGGTTCTCTGTGCAGCAATGTGGC
[0396] ATTGATTCTGTGGCCTTGTGCAGTCAGCTTATGCTCAGCCCATTGATTCCACCACATCCCTGATCGAGGGGA
[0397] CGTTAATTACCTGTCTTTGTGAATTAAGCAGTTTATGAGCAGCAAGTTACTGAGGACCGTAAATAAAGTCATA
[0398] GAGAGCTCAAGGAAGTAATAGCTTCGGTTTAATCATCTGCTTCAAAGGTGCCAATTTTTACATACTACTATAT
[0399] GTAATGATTTGTTCTAAATTGCTTGTTCCTTTTGAAAAAAATTTAAGGATGTTTTATGAAAATGACCATGGAG
[0400] GTCTCCTGCTTAACCAATATACTTTATATTTATAGTTAGAGGGCCCCTCCTTGATAGATTTGAATGAGGAGCT GGAAAGCTTGGGTACAATTTTCATGACTAGTTTGTATTATCTCTGCAAGCCAAAAGGTGTATTAGCAGTCAG
[0401] AATACAGCACTTTACAGAACTGGATTTTTTAAATGTATAAGTTTCCAGGTCTAGGATATTATTTAGCACTTTG
[0402] AAAGTTCCCCTTTTAAAATATATATATAAGAATAATCAAACGAGAAAAATGTACTCATAAAAACACAAAATGT
[0403] GTTTCTTCTGAATGTTTCAAATGTATTCTAAAATATGGTTTCTATAGATAATATTATGGTAGATAACTGGATA
[0404] GTACTTTTTTACTTTCTGAGTCTGTACAGTCTAATCTTCCTGAATGTTTGGGCTGTTTAATTTCTTTAAAGAT
[0405] GATAAATATTACCCGGTCATCCATCATGCTCTATCTATAGGCTATACCATTCATATGTTGGGCAATGCTGTAT
[0406] TATAAAACACATGTAAACATGTATGTAACCCATGTTTAACCCAGCGTAGTTGTAGCATGTGGTTGTATTAATG
[0407] AACGTTACAGGAGAGCTTTATAATCATTTATAAATCTGTAACATTCAATAAAGAAACACATGTTGCAATGATT
[0408] AATTATGTTCCCAATTCCATGTTATTTAGCATCTTTGTGAACCGGGCATTTTTGTTCCTGATCTGCTTGATGC
[0409] TTTTCATGTTCCTTTGGACCACTGTAAAATATGTGTGTAAGCTGATGTATATCCTCTAATGAGTCCTGCGAGC
[0410] TGTGGTAGGCAAGTTGTGATTTTGTGAAAGATGAACTGGCATGTTATGCAAAAGACTATATGACAAATGAAC
[0411] TTAAAATGATATTTTAAACTCCAGTTGAATTAGCTGTTTACATCTGCCAACCCCATGCAGAAGCAGTGTACAG
[0412] TATTTTATAAATATGTTCATTTAGTAACACTATGTTGTTTCTAGATAAAGTGATACTAGTGTGTAGGTGGTTA
[0413] TATATTTGGCCTAGATATTGCATTATAACTCACTATCCTTGAACAATAACAATGTGACTGAAATGAAGTAATC
[0414] TCTCTCCAAACCTGGTCTTAATTTTGTGTCAACAAAATGCATGCACTGCTTTATGCATTTCTTTTGACTTTTCT
[0415] AAGGCACTTAACATTTTACTATTGCCTGCTGTGACGCTTAAGCCAGTTAAGAATTCACTCAAACAGTTGGGCT
[0416] TCTTACTATGGGGATTATGTTCAGTTTTGAAAAATTAAAAACAAAAAAAAAGTAACCAAGGGATTTTTAAATC
[0417] TTTTTTTTAAGCACTGAACAAATAATATGAAATAAAGTATTAACTGCAGGTTGTATAGCCATGGGACCCAGAG
[0418] GTGGCAAGCCAACACCTCTTGGGTCTGCCAAGGTCTAGGTGTTGTGCATCTGTGATATATGCAAGACACATT
[0419] TCTGATTCTTCAGAGCTACTGGGTGCAAATTGCTAAGCCGGAGATGAGAGCGAAAAGTCCATTTGTGATAGT
[0420] GCAGAAGTGCGCAGATCGCTGTGAATGTGTGATCCAATGATATGACAAGAGACCTCCCTCCTTGTCTTGTGG
[0421] CTTCTTCACCTTGGGGGTGGGAGGCGTGTGTTTGGGTGTCTGATGAAGCACTGGGTGGTTCTAAAGAGTTT
[0422] ACTCTTTTAGAAAATCATCATTACTAGAAGCCATTCAACATCTGTTAAAGAGAGGAGCCAATTTGCACAGTTT
[0423] TGAAAATGACTGCTCCTAAAATGAGTAGACAAAACTTTCCTCTCAGCCTGCATTGACCTAAGCTTTCTCTTCT
[0424] TTTTACAAGTTGGATATTCTGTCTCTCAGATTGGAGTCAACCAAAAGAAAGGCTGGTTCCAATTAAGGAAAAG
[0425] CAATTTTTTTCTTTTAATTCCTCTCAGAAGGTAGTTGTGTTACCTTTTCTCTGATGATTTCCTTGCACTCATCA
[0426] CTGCTAATGAAAGCAACGTGACTGTTTCTACAGGTCATCTAAGAGAGGATTTTGGTGACCAGGTAATCCAGA
[0427] TGGCAATAAGAATGAGGTGAATTTTCCCTTCCTTACCTTACCTAGTCTACCAGCCTCCTTAAACCTGCAGGCC
[0428] CTTGTGCGTTTGCACAATGTTTGTGTGCTGGAAACTGAAAAGACATGTGTATGGCTAGAAGTCCATAGGCTT
[0429] TGTAAAGAGTGTCAGTGCCAATCAGGACCCATGCCTTCCTCTGGAGGAGACAGGTGGCTGAGGCCTATGGG
[0430] GCAAAGGGGGAAATTCAGCCTTGTGCCTGGATGTGCGGCTTTCTTTCTCCCCTCTTCTTGCTTCTCTTCTCTT
[0431] AGTCTAAGACTAGCTGCTTTTTCACCAGACCAACAGACCCTTGCCCACATTACCTTTATACCTTGTTGACCCT
[0432] CGCACAGTAAGCTGAAACAGCGGCCGCTTGGAAAAAGGCAAACATTTAGACTTTGTCCCAGGCCTGATCTTC
[0433] CCACCAACTTAGCCTCCTCCTGCCTCTACCCCGGCTGGTGTTCACATTGACCTCGTCCAATTTTTGCCTCTCT
[0434] AAATCTCAAGAGTCCTACACATCTTCACCGCAGCTTCCCACACATCATTAAAACCAGCCATCTGCACATAGAC
[0435] TGAGAGGCTGCAAATTCAAACACATGGAGGGGCCGGATCCAGAAAACACAAATGTGTGAACTGGACTGGTGA
[0436] AAGTCAACAGAAGTAGGGTTTGTAAGTAAGGCATGACAGAATACACATCCCACCACAAACACCTTCAAATTCA
[0437] GCTTTCCAAACACTGTCCTAGCCAAACAAACATGTCTGCCAGCAGCATTCAGTCCCAAAGGCAATAGTTTGGG
[0438] ACCTCTGATTTAGAGCCAACAGGATCAGATTCTTGATAGTGACTTGGTGAGTGTACACACAAAATACACTGA
[0439] GAACCGAGAGGGGGGAAAAGAAACTCGCCTTATTCAGAGTTACTCTTGTTCTGAATGATATATGCATGTATA
[0440] TTTGTTAGCCACATAATTCTAAACTTGAACACAGAGTCTTTGTGAGAGAGATTCAGAAGAAGAGTACCATAGC
[0441] ATGGTATGAAGACTTACCTGCTTCCTGTCACTACTGCGTCTGACCTGAGTTTATATTGCTGCTACCGCTGTGT
[0442] AAAAACAGTACGTGCAGTATACTGTACTCATAGCCATTTCATAATATAGGACCTAGACTCTCATTTGTAAACG
[0443] TTCTAACCCTAGTTTATAATGGGGGAAATTATTCAGATATCATTTTTAAATGAATTCCTACAAATACAATGGT
[0444] TTTAAAATTGGGTTTGCTGAATATATATACATCTTTTCCTTCTTTGTGTATGGATGGACCACGGTATGCATAT CTATCGACACTATAAATATATATAAATCCTTAGAAGAATTGTTCTTTTTTAAAGGTCTATTATTGGATTCACAA
[0445] TGCACTTTGAGTTTGATTGTTTAGATATACAATTCAGAGCAGAAGTTGGCAGATACCACGGGAAAAACTTTCT
[0446] GAAATTTCTGTAACAAATGTTTTGCAATAAAAAAAAAAACTCAGTAGTTTAAAACA
[0447] SEQ ID NO: 68 Nucleotide sequence of exon 29 of the human TRPM3 gene where exon 30 is used
[0448] GGTGGAGAACATGTCTATGCGGCTGGAGGAAGTCAACGAGAGAGAGCACTCCATGAAGGCTTCACTCCAGA
[0449] CCGTGGACATCCGGCTGGCGCAGCTGGAAGACCTTATCGGGCGCATGGCCACGGCCCTGGAGCGCCTGACA
[0450] GGTCTGGAGCGGGCCGAGTCCAACAAAATCCGCTCGAGGACCTCGTCAGACTGCACGGACGCCGCCTACATT
[0451] GTCCGTCAGAGCAGCTTCAACAGCCAGGAAGGGAACACCTTCAAGCTCCAAGAGAGTATAGACCCTGCAG
[0452] SEQ ID NO: 69 Nucleotide sequence of exon 30 of the human TRPM3 gene
[0453] AGCATCCTCTTTATTCAGTATAAGCCGGCAGCAAGCAGTTCTACCTAACGTCCCACATCCTTCTCATGCCAAC
[0454] ACTTCTGTAATTGATCATTATAAAGAAAAAACAAGGTAACAGTCATAGTTCACCTGTCTCTTATCTATTCACTT
[0455] CTGGTGCCACAACTGTTTATCCTTTTTTGAAGAAAATAAGGGAACAGAAATGCCTTTTTGTATTGCAATCGAA
[0456] ATGAAAGAAGAGTTGATGTTAAAAAAACAAAAGTCAAGTGATTTATTATATACAGTGGGCGTTCAAGTCTAGT
[0457] CGAGCAAGCTCAGGAGAATGTAATTAAATAATTTTATATTTTTTAATTTATTTTGTATCTCACCTGTCATGGA
[0458] TGAATTCATTCACTGAATATGTAATATTGAACTTAAAAAAAAAAAAAAAAAAACAGTGGACAGAACTAGCCTG
[0459] AAATTGCCATGTGGGATGTTCTGTTCTCACCGTTCATGTCGTGTGTTGTGCTGCTGTGTGACCGTCATCATT
[0460] TGCATGGCTCCACCACGTCCTCCTGAACACCTCCAAGACGTAACTGCCAATTTTTCACACCACTCATCACATG
[0461] ACCATTTTGTATATGAATATATGGTTATATGTGGATATTTTCATACCTAGAGTTTTGCCATCTAATCTGAGCT
[0462] CAGCATAAATTTAATTGGAGTTTTTCAAGGGCTGGTATCTTTTCTATGGAAATGTTCCAAAGTACTTTTTAAG
[0463] GAAGTTTCAAAACTATAAATAACCTTAGATTTGACTGGGAGTTTGGTATCAACCCAAAGCCATCAGTTGCAAG
[0464] CATACCATGAATATTTTTCTTATAGACAGAGCTATAAAAAAAGATACAGTAGACCAAAATAGAAAGCAAATAA
[0465] ACCATATAAAGAGTTCTATAGTATATGCCACTTATACACATGTATATGCATTTATGCAGAGACACATATTTAT
[0466] ATATAAAATAAATGGACATAAAGAGCTTTCTTAAGAGGCTTGGACTTTTCTATCACCTTGAAGTATAATCAAG
[0467] ATTTTTTTTAATATACAAGAAGTTCCATTGAAAGAGTTCATTATACTATTAGACCAAATGTTGAAATTATGAAT
[0468] TTTTTAAATTCCTATGACTTTTCCTCATATCAAACTAGAGTTGTCAAAATGACTCACTGCTCGCCTTCTGCCCT
[0469] TTTTTGTCTGAAATCACTCACTATCAGGACATCTCATTTAGTCTCGCTTTTCCTAAACAAAGTTTTTACACCAC
[0470] GTACAATCTGAATAGACACGCAACTTTAAACCAGCTAGTGTTACAGACTCTAAAGTAGAGGCATAATCTTCTA
[0471] GATCAGAATCTGGATTGGAAGTGGGATAAAGAAATCTTGACCCCAAATCTTTGGATTCCTATTTGGCTCATTA
[0472] ACGTTTAAAAAAGAATAAAGCCTTTAAGGAAAACAATCTATTGTTCCTGGCCTGAGATACTACCTGGTTCTTT
[0473] TGTTTAATTATAATTGAAAACACCAAGTTTTACTTTATTTTGTGAAATCAAGTAAATACATGGCCTTTAAATAT
[0474] AAGATAAAAAACAAAATAAAAACTCTTCTGAATAAGCATTTCAGGTATAAAAATTGTGATGAGGTCACATATG
[0475] TAAAGAATTAAACAATTCCTTTTTCACTCCTTGGCATTTAGGTGAATTGCTAACAAACACCCAGACTCCCTTA
[0476] TTTACAGCTGTTCTAGAAACACTTAACATTTTATTGGGCCCCACGCTGGCTATTTCCCTCTCAGCAAACATGC
[0477] ACTGGGTCTGAGAATAAATCAGTCGTTCTTAAACTTCCTTGAGTCATGAATCCCTACGAGGCTCTACGATAAC
[0478] TCTAGGCTCTCTCTCCAGAAAGAAAAAAAAAATGTACATAATGCAAAGTTGCAATATAACTTGAAAGGGTTCA
[0479] TGAGCCCCTGGTTCTATATTGATTATGAGGGAAAGGAACCATGTTTGCTCGTAGTTAATGCAGTTGTAATAG
[0480] GCACTTTACATTTGAGACCATCTCTCTGTGATTCTCAGGAAGGCCAAATCTCAGCACCAGAGTTTGAACAAAG
[0481] ATTTTGTTATTTTTGTTCTTTAAATTAGATGTTGCCAATTTAATGCACTTACATCCTAACATGTTGATGATTTT
[0482] AAGTATCAAGCACAATCACAATGCTGAAGTCTCCCTGAAGGGTCTATAGAGGAATCCAAGAAGGAGGTGAAA
[0483] ACATTATTCATTGACATCAAACACCTCCAAGGCCTCATTCTGGGCCAGATTGGAAGTGAGGGAAAGAAATTTT
[0484] CAGCTCAAGTGTTTCCATTCATCGTGATTTCAGAGAGAAAAGGATAGGAACTGGGAAACGAAATACTCAACA
[0485] GTCCTGATCTTGCAATTACCTGATTCTTTTGTTGTGCATGAAAATTAAGTTCTAACGTCTGTGAAACGTGTGA
[0486] AATATATAAGCCAAACTTAAATGACTGTAGACACAAACTGTGTAACTTCCATGAGCCATTTCCTTCCTGTGCA CATGTATGTGTGTTATTTTTCAGTCCATTTCCTTCCATTTCTGGGTTCTCTGTGCAGCAATGTGGCATTGATT
[0487] CTGTGGCCTTGTGCAGTCAGCTTATGCTCAGCCCATTGATTCCACCACATCCCTGATCGAGGGGACGTTAAT
[0488] TACCTGTCTTTGTGAATTAAGCAGTTTATGAGCAGCAAGTTACTGAGGACCGTAAATAAAGTCATAGAGAGC
[0489] TCAAGGAAGTAATAGCTTCGGTTTAATCATCTGCTTCAAAGGTGCCAATTTTTACATACTACTATATGTAATG
[0490] ATTTGTTCTAAATTGCTTGTTCCTTTTGAAAAAAATTTAAGGATGTTTTATGAAAATGACCATGGAGGTCTCC
[0491] TGCTTAACCAATATACTTTATATTTATAGTTAGAGGGCCCCTCCTTGATAGATTTGAATGAGGAGCTGGAAAG
[0492] CTTGGGTACAATTTTCATGACTAGTTTGTATTATCTCTGCAAGCCAAAAGGTGTATTAGCAGTCAGAATACAG
[0493] CACTTTACAGAACTGGATTTTTTAAATGTATAAGTTTCCAGGTCTAGGATATTATTTAGCACTTTGAAAGTTC
[0494] CCCTTTTAAAATATATATATAAGAATAATCAAACGAGAAAAATGTACTCATAAAAACACAAAATGTGTTTCTTC
[0495] TGAATGTTTCAAATGTATTCTAAAATATGGTTTCTATAGATAATATTATGGTAGATAACTGGATAGTACTTTT
[0496] TTACTTTCTGAGTCTGTACAGTCTAATCTTCCTGAATGTTTGGGCTGTTTAATTTCTTTAAAGATGATAAATA
[0497] TTACCCGGTCATCCATCATGCTCTATCTATAGGCTATACCATTCATATGTTGGGCAATGCTGTATTATAAAAC
[0498] ACATGTAAACATGTATGTAACCCATGTTTAACCCAGCGTAGTTGTAGCATGTGGTTGTATTAATGAACGTTAC
[0499] AGGAGAGCTTTATAATCATTTATAAATCTGTAACATTCAATAAAGAAACACATGTTGCAATGATTAATTATGT
[0500] TCCCAATTCCATGTTATTTAGCATCTTTGTGAACCGGGCATTTTTGTTCCTGATCTGCTTGATGCTTTTCATG
[0501] TTCCTTTGGACCACTGTAAAATATGTGTGTAAGCTGATGTATATCCTCTAATGAGTCCTGCGAGCTGTGGTA
[0502] GGCAAGTTGTGATTTTGTGAAAGATGAACTGGCATGTTATGCAAAAGACTATATGACAAATGAACTTAAAAT
[0503] GATATTTTAAACTCCAGTTGAATTAGCTGTTTACATCTGCCAACCCCATGCAGAAGCAGTGTACAGTATTTTA
[0504] TAAATATGTTCATTTAGTAACACTATGTTGTTTCTAGATAAAGTGATACTAGTGTGTAGGTGGTTATATATTT
[0505] GGCCTAGATATTGCATTATAACTCACTATCCTTGAACAATAACAATGTGACTGAAATGAAGTAATCTCTCTCC
[0506] AAACCTGGTCTTAATTTTGTGTCAACAAAATGCATGCACTGCTTTATGCATTTCTTTTGACTTTTCTAAGGCA
[0507] CTTAACATTTTACTATTGCCTGCTGTGACGCTTAAGCCAGTTAAGAATTCACTCAAACAGTTGGGCTTCTTAC
[0508] TATGGGGATTATGTTCAGTTTTGAAAAATTAAAAACAAAAAAAAAGTAACCAAGGGATTTTTAAATCTTTTTT
[0509] TTAAGCACTGAACAAATAATATGAAATAAAGTATTAACTGCAGGTTGTATAGCCATGGGACCCAGAGGTGGC
[0510] AAGCCAACACCTCTTGGGTCTGCCAAGGTCTAGGTGTTGTGCATCTGTGATATATGCAAGACACATTTCTGA
[0511] TTCTTCAGAGCTACTGGGTGCAAATTGCTAAGCCGGAGATGAGAGCGAAAAGTCCATTTGTGATAGTGCAGA
[0512] AGTGCGCAGATCGCTGTGAATGTGTGATCCAATGATATGACAAGAGACCTCCCTCCTTGTCTTGTGGCTTCT
[0513] TCACCTTGGGGGTGGGAGGCGTGTGTTTGGGTGTCTGATGAAGCACTGGGTGGTTCTAAAGAGTTTACTCT
[0514] TTTAGAAAATCATCATTACTAGAAGCCATTCAACATCTGTTAAAGAGAGGAGCCAATTTGCACAGTTTTGAAA
[0515] ATGACTGCTCCTAAAATGAGTAGACAAAACTTTCCTCTCAGCCTGCATTGACCTAAGCTTTCTCTTCTTTTTA
[0516] CAAGTTGGATATTCTGTCTCTCAGATTGGAGTCAACCAAAAGAAAGGCTGGTTCCAATTAAGGAAAAGCAAT
[0517] TTTTTTCTTTTAATTCCTCTCAGAAGGTAGTTGTGTTACCTTTTCTCTGATGATTTCCTTGCACTCATCACTGC
[0518] TAATGAAAGCAACGTGACTGTTTCTACAGGTCATCTAAGAGAGGATTTTGGTGACCAGGTAATCCAGATGGC
[0519] AATAAGAATGAGGTGAATTTTCCCTTCCTTACCTTACCTAGTCTACCAGCCTCCTTAAACCTGCAGGCCCTTG
[0520] TGCGTTTGCACAATGTTTGTGTGCTGGAAACTGAAAAGACATGTGTATGGCTAGAAGTCCATAGGCTTTGTA
[0521] AAGAGTGTCAGTGCCAATCAGGACCCATGCCTTCCTCTGGAGGAGACAGGTGGCTGAGGCCTATGGGGCAA
[0522] AGGGGGAAATTCAGCCTTGTGCCTGGATGTGCGGCTTTCTTTCTCCCCTCTTCTTGCTTCTCTTCTCTTAGTC
[0523] TAAGACTAGCTGCTTTTTCACCAGACCAACAGACCCTTGCCCACATTACCTTTATACCTTGTTGACCCTCGCA
[0524] CAGTAAGCTGAAACAGCGGCCGCTTGGAAAAAGGCAAACATTTAGACTTTGTCCCAGGCCTGATCTTCCCAC
[0525] CAACTTAGCCTCCTCCTGCCTCTACCCCGGCTGGTGTTCACATTGACCTCGTCCAATTTTTGCCTCTCTAAAT
[0526] CTCAAGAGTCCTACACATCTTCACCGCAGCTTCCCACACATCATTAAAACCAGCCATCTGCACATAGACTGAG
[0527] AGGCTGCAAATTCAAACACATGGAGGGGCCGGATCCAGAAAACACAAATGTGTGAACTGGACTGGTGAAAGT
[0528] CAACAGAAGTAGGGTTTGTAAGTAAGGCATGACAGAATACACATCCCACCACAAACACCTTCAAATTCAGCTT
[0529] TCCAAACACTGTCCTAGCCAAACAAACATGTCTGCCAGCAGCATTCAGTCCCAAAGGCAATAGTTTGGGACCT
[0530] CTGATTTAGAGCCAACAGGATCAGATTCTTGATAGTGACTTGGTGAGTGTACACACAAAATACACTGAGAAC CGAGAGGGGGGAAAAGAAACTCGCCTTATTCAGAGTTACTCTTGTTCTGAATGATATATGCATGTATATTTG
[0531] TTAGCCACATAATTCTAAACTTGAACACAGAGTCTTTGTGAGAGAGATTCAGAAGAAGAGTACCATAGCATG
[0532] GTATGAAGACTTACCTGCTTCCTGTCACTACTGCGTCTGACCTGAGTTTATATTGCTGCTACCGCTGTGTAAA
[0533] AACAGTACGTGCAGTATACTGTACTCATAGCCATTTCATAATATAGGACCTAGACTCTCATTTGTAAACGTTC TAACCCTAGTTTATAATGGGGGAAATTATTCAGATATCATTTTTAAATGAATTCCTACAAATACAATGGTTTT
[0534] AAAATTGGGTTTGCTGAATATATATACATCTTTTCCTTCTTTGTGTATGGATGGACCACGGTATGCATATCTA
[0535] TCGACACTATAAATATATATAAATCCTTAGAAGAATTGTTCTTTTTTAAAGGTCTATTATTGGATTCACAATGC
[0536] ACTTTGAGTTTGATTGTTTAGATATACAATTCAGAGCAGAAGTTGGCAGATACCACGGGAAAAACTTTCTGAA
[0537] ATTTCTGTAACAAATGTTTTGCAATAAAAAAAAAAACTCAGTAGTTTAAAACATGA
Claims
CLAIMS1. An inhibitor of human TRPM3 for use in the treatment of epilepsy.
2. Use of an inhibitor of human TRPM3 in the manufacture of a medicament for use in the treatment of epilepsy.
3. A method for treating epilepsy in a subject, which method comprises administering to said subject a therapeutically effective amount of an inhibitor of human TRPM3.
4. A method according to claim 3, wherein the subject is a human subject.
5. An inhibitor of human TRPM3 for use according to claim 1, use according to claim 2 or a method according to claim 3, wherein the inhibitor of human TRPM3 has a binding affinity at human GABAA receptors of > 10 pM.
6. An inhibitor of human TRPM3 for use according to claim 1 or claim 5, use according to claim 2 or claim 5 or a method according to any one of claims 3 to 5, wherein the inhibitor of human TRPM3 is not primidone or a pharmaceutically acceptable salt thereof, or phenobarbital or a pharmaceutically acceptable salt thereof.
7. An inhibitor of human TRPM3 according to any one of claims 1, 5 or 6, use according to any one of claims 2, 5 or 6 or a method according to any one of claims 3 to 6, wherein treatment of epilepsy refers to the treatment of generalized tonic-clonic seizures.
8. An inhibitor of human TRPM3 according to any one of claims 1 or 5 to 7, use according to any one of claims 2 or 5 to 7, or a method according to any one of claims 3 to 7, wherein the human subject has a TRPM3 allele with a gain of function mutation.
9. An inhibitor of human TRPM3 for use according to claim 8, use according to claim 8 or a method according to claim 8, wherein the mutated version of human TRPM3 has one or more of the following amino acid substitutions: D602V, L757V, R1670Q, A1645V, V990M / G / L, G995S, P1090Q, N1114D and SI 12 IP (numbering based on SEQ ID NO: 2).
10. An inhibitor of human TRPM3 for use according to any one of claims 1, or 5-9, use according to any one of claims 2, or 5-9, or a method according to any one of claims 3-9, wherein the inhibitor of human TRPM3 is administered as adjunctive therapy with another anti-epileptic drug.
11. An inhibitor of human TRPM3 for use according to claim 10, use according to claim 10 or a method according to claim 10, wherein the anti-epileptic drug is selected from the group consisting of: lamotrigine, levetiracetam and sodium valproate.
Citation Information
Patent Citations
Polynucleotides encoding novel variants of the TRP channel family member, ltrpc3
WO2005026317A2
Aryl derivatives for treating TRPM3 mediated disorders
WO2022112345A1
Heterocycle derivatives for treating TRPM3 mediated disorders
WO2022112352A1
Inhibitors of TRPM3 and their uses
WO2022152715A1
New derivatives for treating TRPM3 mediated disorders
WO2023227698A1
